CT or MRI within 14 days prior to start of study drug
Evidence of metastatic breast cancer; patient considered at high risk of having disseminated disease (i.e. those with locally advanced disease, clinical N2-3 or pathological N1-3 with the exception of pN1a in adjuvant patients) should have a CT/MRI scan of the thorax/abdomen/pelvis or any other area as clinically indicated and a bone scan or a CT scan with bone windows at any point between diagnosis of the current breast cancer and randomization to rule out metastatic breast cancer; (note PET/CT scan may be used as an alternative imaging technique and precludes the need for bone scan); patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, CT or MRI at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note PET CT scan may be used as an alternative imaging technique)
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; if an MRI is being obtained to verify eligibility, it is recommended that the MRI parameters follow the specifications detailed in the protocol so that the patient will not require a repeat MRI prior to treatment start
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply: \r\n* They have recovered from the effects of surgery\r\n* A minimum of 28 days have elapsed from the day of surgery to the day of registration step 2; for core or needle biopsy, a minimum of 7 days must have elapsed prior to registration step 2\r\n* Residual disease following resection of recurrent ependymoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a CT/ MRI should be done no later than 96 hours in the immediate post-operative period or at least 4 weeks post-operatively, within 14 days prior to consent; if the \within 96-hour after surgery\ scan is more than 14 days before consent, the scan needs to be repeated; if the steroid dose is increased between the date of imaging and consent, a new baseline MRI/CT is required on a stable steroid dosage for at least 5 days
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST 1.1.
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI contraindicated) within 14 days prior to start of study drug; corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and initiation of study treatment, a new baseline MRI/CT is required
CT or MRI of the neck to confirm staging
Measurable disease by CT or MRI
No definitive evidence of metastases on screening CT or MRI of abdomen/pelvis and radionuclide whole body bone scan per the judgment of the investigator. Abdominal and/or pelvic lymph nodes measuring 2 cm or less in short axis diameter are allowed. Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not visualized on CT and/or MRI or radionuclide bone scan are allowed. Equivocal lesions on bone scan should be followed up with additional imaging as clinically indicated.
Patients must have prior CT scan images available for investigators to collect
Unequivocal evidence of tumor progression as documented by biopsy or brain MRI scan per Revised Assessment in Neuro-Oncology (RANO) criteria
MRI-guided cryoablation criteria-cohort 1: \r\n* Participants must have a mass that is well-visualized under MRI; since PET-CT guidance requires the nuclear medicine department to administer a radionuclide material, either fluorodeoxyglucose (FDG) or a somatostatin analog (DOTATATE), the default will be to try to use MRI guidance which will be simpler
Patient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan ?4 weeks prior to entry into the study
Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any time (past or present).
At least 2 measurable lesions as defined per modified RECIST 1.1 by CT or MRI performed after the last line of anti-cancer therapy within 28 days of enrollment
Measurable disease detected by imaging exam (CT or MRI).
Stenosis or occlusion in intended artery for treatment that precludes IA therapy as determined by CT or MRI
Inability to exclude major side branches in the area of the intended RenovoCath™ occlusion as determined by CT or MRI
No suitable artery with a diameter greater than 4mm in proximity of at least one side of the tumor as determined by CT or MRI
Patients must have measurable disease, defined as tumor mass which is > 10 mm with spiral CT scan or MRI. Baseline imaging scan must be within 8 weeks of registration.
Patients who are not able to receive an MRI scan
No radiographic evidence of metastatic disease by computed tomography (CT) scan and bone scan, performed within the prior 4 weeks
For subjects enrolled for tumor progression, progression is defined as: \r\n* Presence of new plexiform neurofibroma on MRI or computed tomography (CT) (documented by comparison with prior MRI or CT), OR \r\n* A measurable increase in plexiform neurofibroma size (>= 20% increase in the volume, or a >= 13% increase in the product of the two longest perpendicular diameters, or a >= 6% increase in the longest diameter) documented by comparison of two scans (MRI or CT) in the time period of approximately one year or less prior to evaluation for this study
Patient must have documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease as established by CT or MRI scan
Participants must have shown unequivocal evidence for tumor progression by MRI or computed tomography (CT) scan
CT or MRI within 14 days prior of registration; NOTE: participants may be registered if screening CT or MRI is > 14 days of registration if prospective approval is received from overall principal investigator (PI), Dr. Patrick Wen (for prospectively approved circumstances an eligibility exception will not need to be filed)
Patients having undergone recent resection of recurrent or progressive tumor will be eligible given all of the following conditions apply:\r\n* At least 2 weeks (14 days) have elapsed from the date of surgery and the patients have recovered from the effects of surgery\r\n* Evaluable or measurable disease following resection of recurrent malignant glioma is not mandated for eligibility into the study\r\n* To best assess the extent of residual disease post-operatively, a magnetic resonance imaging (MRI) should be done no later than 96 hours in the immediate post-operative period or at least within 4 weeks post-operatively, within 14 days prior to registration; if the 96-hour scan is more than 14 days before registration, the scan needs to be repeated; the patient must have been on a stable steroid dose for at least 5 days prior to the baseline MRI; steroids may be initiated as clinically indicated once baseline imaging has been completed with a goal of titrating steroids as soon as clinically warranted
Locally advanced rectal cancer determined by any of the following features\r\n* Fixed or immobile tumor on physical exam and/or\r\n* T3 disease with invasion through the muscularis propria as defined by transrectal ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI)\r\n* T4 disease with invasion of adjacent structures such as pelvic sidewall, sacrum, pelvis, bladder and/or prostate as determined appropriate imaging modalities such as ultrasound, CT or MRI\r\n* Any T with + N on CT scan/MRI or transrectal ultrasound
Distant metastases, based upon:\r\n* CT scan or MRI of the abdomen/pelvis within 120 days prior to registration and\r\n* Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis prior to registration
Patients must have had radiographic evidence of tumor progression by brain MRI or computed tomography (CT) scan with contrast
Evidence of > grade 1 CNS hemorrhage on baseline MRI on CT scan
Prostate volume: =< 80 cc on transrectal ultrasound\r\n* Measured from ultrasound, CT, or MRI within 3 months
MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1
FOR ARM A: Inability to obtain a planning MRI or a planning MRI of sufficient quality to allow identification of the peripheral zone and urethra, or inability to adequately fuse the MRI to the planning CT scan
Subjects who have minimal CT scan findings suspicious of residual disease are eligible provided there is no evidence of progression of disease by Rustin Criteria, defined as: \r\n* Present CT Scan findings show no change from CT Scan at baseline, and\r\n* Current CA-125 is below institutional upper normal limit and remains unchanged upon two consecutive measurements at least one week apart, and\r\n* CA-125 was above institutional upper normal limit at diagnosis
Equivalent tumor diameter =< 40 mm by CT or MRI measurement, at the time of consultation/screening (for each metastatic lesion present in the brain)
Patient must have had a diagnosis of high risk NB at initial diagnosis or if non-high risk at time of initial diagnosis must have had evidence of metastatic progression when > 18 months of age\r\n* Patient must have measurable or evaluable disease occurring as one of the following:\r\n** Disease progression after initiation of upfront NB therapy defined as:\r\n*** New disease site documented on MIBG scintigraphy; or computed tomography (CT)/magnetic resonance imaging (MRI); or any new bone site that is fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid (in patient known to have MIBG non-avid tumor) AND has MRI findings consistent with tumor OR has a biopsy showing NB or ganglioneuroblastoma\r\n*** Greater than 20% increase in a least one dimension of soft tissue mass documented by CT/MRI AND a minimum absolute increase of 5 mm in longest dimension in existing lesions\r\n*** Bone marrow biopsy meeting revised International Neuroblastoma Response Criteria (INRC) criteria for progressive disease\r\n** Refractory disease such that response to upfront therapy (defined as at least 4 cycles of multi-agent induction chemotherapy) is less than partial response\r\n** Persistence of disease after at least a partial response to frontline therapy (i.e. patient has had at least a partial response to frontline therapy but still has residual disease by MIBG scan, CT/MRI, or bone marrow aspirate/biopsies); patients in this category are REQUIRED to have histologic confirmation of viable NB from at least one residual site; tumor seen on routine bone marrow morphology is sufficient
No distant metastases, based upon:\r\n* CT scan or MRI of the pelvis within 120 days prior to registration\r\n* Bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis
Measurable tumor on MRI or CT scan or X-ray
Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis
Patients deemed as resectable by pancreatic protocol CT or MRI
Patients with histologically proven intracranial glioblastoma, gliosarcoma or anaplastic astrocytoma will be eligible. Patients must have shown unequivocal radiographic evidence for tumor progression by MRI scan. A scan should be performed within 14 days prior to registration and on a steroid dose that has been stable for at least 5 days. If the steroid dose is increased between the date of imaging and registration, a new baseline MRI is required.
Cranial magnetic resonance imaging (MRI) or contrast computed tomography (CT) must have been performed within 21 days of study entry; the use of MRI rather than CT is preferred; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; if the surgical procedure was a resection, cranial MRI or contrast CT performed within 96 hours of resection is preferred but not required; if the surgical procedure was a biopsy only, a head CT within 96 hours of the biopsy is acceptable; patients without measurable or assessable disease are eligible
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; measurable disease is NOT required\r\n* Note: MRI is the preferable imaging method; CT scan may be used in cases where an MRI cannot be obtained
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:\r\n* They have recovered from the effects of surgery and be > 3 weeks from surgery\r\n* Residual disease following resection of recurrent malignant glioma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a CT/ MRI should be done no later than 96 hours in the immediate post-operative period or at least 4 weeks post-operatively, within 14 days prior to registration; if the 96-hour scan is more than 14 days before registration, the scan needs to be repeated; if the steroid dose is increased between the date of imaging and registration, a new baseline MRI/CT is required on a stable steroid dosage for at least 5 days
Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization. An MRI of the liver is required at screening to validate that CT accurately reflects the extent of disease in the liver. For patients with MRI intolerance, a 3-phase liver CT is to be done in place of liver MRI.
Patients with evidence on prior imaging (bone scan, CT, or MRI) suggestive of disseminated disease will not be eligible (imaging not required for eligibility)
No space occupying lesion on computed tomography (CT) scan of the liver i.e. normal CT scan post-resection; small lesion in the liver after resection can be ablated by alcohol injection or radio frequency ablation and can make patient eligible
Tumour stage cT1-T3abN0 based on pelvic MRI
Baseline staging prior to chemoRT initiation must be obtained. If stage IV, there must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable distant disease per RECIST 1.1. Note: Patients with stage IV disease should have limited but measurable metastatic disease (one or two organs involved e.g., liver and lung) and primary tumor deemed resectable.
RANO defined tumor progression by MRI in comparison to a prior scan
Measurable disease by CT or MRI.
Subjects must not have evidence of pneumonitis or inflammatory lung disease on CT scan and x-ray
Computed tomography (CT) scan and MRI of the pelvis within 120 days prior to enrollment (note: [a] if patient has medical contraindication to MRI, an exemption will be granted and enrollment can proceed [b] for patients with PSA < 1.0 ng/mL, the treatment planning CT can substitute for a diagnostic CT scan)
Patients with non-measurable disease < 10 mm on multiparametric MRI or CT scan will be excluded
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan\r\n* For Cohort 2 subjects, CT or MRI within 14 days prior to study registration; for Cohort 2, corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required\r\n* For Cohort 1 subjects, CT or MRI should be performed ideally within 14 days prior to study registration, it is acceptable for this MRI/CT to have been performed greater than 14 days prior to registration if unavoidable; furthermore, fluctuation in corticosteroid dose around this MRI does not warrant repeat scan so long as there is documented unequivocal evidence of tumor progression available
Participants having undergone recent resection or open biopsy or stereotactic biopsy of recurrent or progressive tumor will be eligible for Cohort 2 as long as the following conditions apply:\r\n* They have recovered from the effects of surgery\r\n* Residual disease following resection of recurrent tumor is not mandated for eligibility; to best assess the extent of residual disease post-operatively, an MRI or CT scan should ideally have been performed no later than 96 hours following surgery, or at least 28 days post-operatively, but scans performed outside of this window are considered acceptable if no alternative is available; in either case, the baseline/screening MRI must be performed within 14 days prior to registration; if the participant is taking corticosteroids, the dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
The tumor must be clinically determined to be locally advanced stage II or stage III rectal cancer, and must also meet any ONE of the following criteria:\r\n* Distal location (as defined by measurement on magnetic resonance imaging [MRI], transrectal ultrasound [ERUS]/pelvic computed tomography [CT] [with IV contrast] scan or palpable on digital rectal examination [DRE]): cT3-4 =< 5 cm from the anal verge, any N\r\n* Bulky: any cT4 or evidence that the tumor is adjacent to (defined as within 3 mm of) the mesorectal fascia on MRI or ERUS/pelvic CT (with IV contrast) scan\r\n* High risk for metastatic disease with 4 or more regional lymph nodes (cN2); clinical nodal or \cN\ status for eligibility includes the total number of nodes (N2 = 4 or more) in the mesorectal and superior rectal stations measuring >= 1.0 cm in any axis on cross sectional or endoscopic imaging; Note: nodes must measure 1.0 cm or greater to be considered positive for this eligibility requirement\r\n* Not a candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy (as planned by the primary surgeon)\r\n** Note: clinical stage of the primary tumor and nodes may be determined locally by rectal endoscopic ultrasound or pelvic MRI (MRI is strongly preferred); CT scan with IV contrast is acceptable provided there is evidence of T4 and/or N2 disease
Positive indication of disease on mammogram or MRI scan
A pre-operative magnetic resonance imaging (MRI) scan of the brain with and without contrast is required; NOTE: computed tomography (CT) scans are NOT sufficient for study eligibility\r\n* Post-operative head MRI scan with and without contrast (preferably within 72 hours post-surgery); for patients who undergo stereotactic biopsy only, either a pre or post-operative MRI is sufficient; for patients with M2 and M3 disease, a post-op MRI is strongly encouraged, but not mandatory\r\n* Spinal MRI imaging with and without gadolinium is required within 10 days of surgery if done pre-operatively or within 28 days of surgery if done post-operatively; for posterior fossa tumors, pre-operative MRI scans are preferred
Evidence of any significant intracranial hemorrhage, as determined by the treating investigator, within 6 weeks from registration or as seen on most recent MRI prior to screening/baseline MRI
One or more tumors measurable on CT scan/MRI scan per RECIST v 1.1. - Previously irradiated tumors may be eligible if they have clearly progressed in size.
Measurable disease by CT or MRI
Patients with glioma must have a baseline brain MRI scan
Glioma patients with evidence of intracranial or intratumoral hemorrhage either by MRI or CT scan
No new bleeding on day 28 (D28) (+/-3) MRI (or CT if MRI is contraindicated)
Evidence of CNS hemorrhage on baseline MRI or CT scan (except for post-surgical, asymptomatic Grade 1 hemorrhage that has been stable for at least 3 months for subjects enrolled prior to Amendment 2 and for at least 4 weeks in subjects enrolled after Amendment 2 is approved).
Patients must have a contrast enhanced CT scan or MRI or PET/CT scan of the tumor site and neck nodes prior to entering the study.
CT scan or Ultrasound-based volume estimation of prostate gland ? 100 grams;
CT scan that demonstrates no evidence of disease (NED) after completion of adjuvant therapy Note: This CT scan will also be used for Texture analysis.
Patients with radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days before the start of study treatment.
Participants must have a progression by MRI or computed tomography (CT) scan; a scan must be performed within 21 days prior to cycle 1, day 1 (C1d1) and on a steroid dose that has been stable for at least 5 days; if the steroid dose is increased between the date of imaging and C1d1, a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; a patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans
Measurable disease on CT or MRI scan by RECIST criteria (required for Phase 1b only).
Patients should undergo a repeat MRI prior to enrollment if there is a significant worsening or new neurologic symptoms in the interval between the eligibility scan and start of protocol therapy\r\n* The repeat scan will act as a new baseline and the eligibility scan for these patients
Measurable disease by CT or MRI
CT or MRI within 14 days prior to start of study drug; MRIs should include vascular imaging when possible; corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Participants having undergone recent resection of recurrent or progressive tumor will be eligible as long as the following conditions apply:\r\n* They have recovered from the effects of surgery\r\n* Residual disease following resection of recurrent tumor is not mandated for eligibility; to best assess the extent of residual disease post-operatively, an MRI or CT scan should be done no later than 96 hours following surgery or at least 4 weeks post-operatively, in either case within 14 days prior to start of study drug; if the participant is taking corticosteroids, the dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Patients must have shown unequivocal evidence for contrast enhancing tumor progression by MRI (or CT for patients who cannot tolerate MRI) in comparison to a prior scan; the same type of scan, i.e., MRI (or CT for patients who cannot undergo MRI) must be used throughout the period of protocol treatment for tumor measurement; criteria defined for progression on this study are not mandatory for eligibility if the disease progression is obvious in the opinion of the investigator and the Sponsor
An MRI/CT scan showing progression is required; stable corticosteroids are not required
For subjects enrolled for tumor progression, progression is defined as:\r\n* Presence of new plexiform neurofibroma on MRI or computed tomography (CT) (documented by comparison with prior MRI or CT), OR\r\n* A measurable increase in plexiform neurofibroma size (>= 20% increase in the volume, or a >= 13% increase in the product of the two longest perpendicular diameters, or a >= 6% increase in the longest diameter) documented by comparison of two scans (MRI or CT) in the time period of approximately one year or less prior to evaluation for this study
Detectable metastases by bone scan, CT-scan or MRI
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST criteria.
At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing.
Patients must have shown unequivocal radiographic evidence for tumor progression by MRI or CT scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:\r\n* They have recovered from the effects of surgery and be > 28 days from surgery\r\n* Residual disease following resection of recurrent GBM or GS is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a CT/ MRI should be done no later than 96 hours in the immediate post-operative period or at least 4 weeks post-operatively, within 14 days prior to registration; if the 96-hour scan is more than 14 days before registration, the scan needs to be repeated; if the steroid dose is increased between the date of imaging and registration, a new baseline MRI/CT is required on a stable steroid dosage for at least 5 days
Unequivocal evidence of tumor progression by MRI scan
Histologically confirmed, metastatic prostate cancer (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis).
Radiographic evidence of metastatic disease, detectable by bone scan, CT scan, or MRI. At least one site of metastatic disease must be amenable to needle biopsy.
A diagnostic contrast-enhanced MRI or CT scan of the brain must be performed preoperatively and postoperatively prior to the initiation of radiotherapy, within 28 days (preferably 14 days) prior to C1D1.
Unresectable, locally advanced measurable (at least bidirectional) adenocarcinoma of the pancreas (regardless of site) proven by biopsy or cytology and confirmed by surgical consultation\r\n* Unresectability is defined as dual phase CT or magnetic resonance imaging (MRI) evidence of direct extension to the superior mesenteric artery (SMA) and/or celiac axis with absence of a fat plane between the low-density tumor and these arterial structures, or loss of patent and/or thrombosed superior mesenteric-portal vein confluence; if CT or MRI performed at the outside hospital is not of acceptable quality according to review of study radiologist (i.e. if it is not a triple phase contrast-enhanced CT with isotropic reformations in all three orthogonal planes, or a contrast-enhanced MRI with at least two post-contrast three-dimensional T1-weighted phases), it will be repeated at Indiana University Simon Cancer Center (IUSCC); if the CT or MRI is of sufficient quality for the study radiologist, a repeat interpretation will be done by the study radiologist to ensure accurate staging; CT scan will be preferred over MRI for study entry when possible, but either is permissible; the same study modality used for entry will be used to follow patients throughout the study\r\n* Patient has not received previous treatment for PC\r\n* Patients who have been surgically explored and deemed unresectable on that basis are eligible, provided other entry criteria are met\r\n* The tumor must be measurable (bidirectional) and measure between 25 mm and 70 mm in maximal diameter\r\n* All patients with a dilated bile duct or elevated total bilirubin will have a biliary stent or transhepatic stent placed before consideration for the trial; when possible, a metal biliary stent will be placed before study treatment
Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made\r\n* Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced MRI scan (or CT scan for patients with non-compatible devices) within 21 days prior to registration; Note: patients who did have surgery with a post-operative contrast-enhanced scan falling outside the 5-week window prior to registration, per definition of recent surgery, must have a repeat magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) within 21 days prior to registration\r\n* Patients must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:\r\n** New areas of tumor outside the original radiotherapy fields as determined by the investigator, or\r\n** Histologic confirmation of tumor through biopsy or resection, or\r\n** Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration\r\n* Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement
Patients having undergone recent resection of their glioblastoma (within 5 weeks prior to registration) must have recovered from the effects of surgery; for CNS related core or needle biopsies, a minimum of 7 days must have elapsed prior to registration\r\n* Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative or intra-operative MRI scan (or CT scan for patients with non-compatible devices) must be performed prior to registration and should be within 96 hours post surgery (although 24 hours would be optimum)
Only untreated patients with high risk pancreatic adenocarcinomas will be eligible for the study; for this study, such patients are defined as those who meet one or more of the following radiographic or serologic criteria:\r\n* Primary tumor that involves the superior mesenteric vein causing a vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction\r\n* Primary tumor that involves =< 180 degrees of the superior mesenteric artery (SMA), celiac axis or any of its branches on CT or magnetic resonance imaging (MRI)\r\n* Primary tumor that abuts or encases (>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)\r\n* Patients with a high cancer antigen 19-9 (CA19-9) (>= 500 mg/dl) in the presence of a bilirubin =< 2.0 mg/dL\r\n* Radiographic findings consistent with malignant peripancreatic lymphadenopathy outside the planned field on CT or MRI\r\n* Radiographic findings of indeterminate liver or peritoneal lesions on CT or MRI concerning but not diagnostic of metastatic disease
Patients cannot have known hepatic or peritoneal metastases detected by ultrasound (US), CT scan, MRI or laparotomy
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdominal CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) and staging laparoscopy; all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese) and laparoscopy; only potentially resectable patients are eligible; potentially resectable is defined as \r\n* No extrapancreatic disease\r\n* No evidence (on CT) of involvement of the celiac axis or spinal muscular atrophy (SMA) \r\n* No evidence (CT or MRI) of occlusion of the superior mesenteric vein (SMV) or superior mesenteric-portal vein (SMPV) confluence, and \r\n* No evidence of gross peritoneal or distant metastases on staging laparoscopy or laparotomy
MRI scan with gadolinium contrast showing geographically-circumscribed tumor =< 40 cc incorporating both enhancing and non-enhancing volume; this is calculated by the product of maximum measurements in 3 dimensions divided by 2; tumors exceeding this limit may be eligible and any question should be directed to a radiation oncology investigatory and the MSK principal investigator (PI); (the MRI must be performed on a steroid dosage that has been stable or decreasing for at least 5 days; patients on no steroids are eligible; if the steroid dose is increased between date of imaging and registration, a new baseline MRI is required)
Glioma showing prior spontaneous hemorrhage as determined from the clinical history or from any preoperative computed tomography (CT) or MRI scan (excluding grade 1 punctate, incidentally found)
Inability to complete a MRI or CT scan with contrast of the head
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and first dose of plerixafor, a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; a patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans
For patients enrolled in Part 2 (surgical substudy), CT or MRI should be performed ideally within 14 days prior to study registration, but because the screening MRI for this subset of subjects will not be used for evaluation of response, it is acceptable for this MRI/CT to have been performed greater than 14 days prior to registration if unavoidable; furthermore, for this same reason, fluctuation in corticosteroid dose around this MRI does not warrant repeat scan so long as there is documented unequivocal evidence of tumor progression available
These laboratory values must be obtained within 28 days prior to registration; patients with levels of one or more of these enzymes greater than institutional upper limit of normal (IULN) may still be enrolled if metastatic disease is excluded with appropriate imaging which may include dedicated liver imaging, bone scan, PET, CT, MRI, or biopsy when appropriate
All active liver lesions must be discrete on CT or MRI imaging
Cranial MRI or contrast CT must have been performed within 21 days of study entry; the use of MRI rather than CT is preferred; the same type of scan, i.e., MRI or CT, must be used throughout the period of protocol treatment for tumor measurement; if the surgical procedure was a resection, cranial MRI or contrast CT performed within 96 hours of resection is preferred, but not required; patients without measureable or assessable disease are eligible
CT or MRI evidence of metastatic disease to the bone
No evidence of locoregional disease or distant metastases at screening. Subjects must have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung metastases. A negative biopsy will be mandated in patients with a positive scan. Other evaluations should be performed as clinically indicated.
Metastatic Disease with at least one lesion on bone scan and/or soft tissue on CT/MRI
Every patient with relapse or progression into the CNS must be documented with computed tomography (CT) scan or MRI of the brain; other sites of relapse may be evaluated, including bone marrow
Cohort Expansion: One or more tumors measurable on CT/MRI scan per RECIST v 1.1 (Eisenhauer 2009; Appendix C).
Measurable disease by CT or MRI
Uneqivocal evidence of a first tumor recurrence or progression on the initial treatment regimen (prior to enrollment on this study), consisting of surgical intervention (biopsy and/or resection), radiation, and temozolomide chemotherapy, as assessed by MRI or CT scan of the brain with or without contrast within 14 days prior to the start of SL-701. If receiving corticosteroids, the dose must be stable or decreasing for at least 5 days prior to the scan. Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided CT scans are obtained and are of sufficient quality. For each patient, the same imaging technique should be performed throughout the study, for purposes of assessing tumor response or PD.
No evidence of hemorrhage on the baseline MRI or CT scan other than those that are Grade ? 1 and either post-operative or stable on at least two consecutive scans.
For patients who have undergone or will undergo stereotactic biopsy of recurrent or progressive tumor, a post-operative magnetic resonance imaging (MRI) is not required, provided that the pre-biopsy MRI is within 21 days of registration; if the preoperative scan is more than 21 days before registration, the scan needs to be repeated; if the steroid dose is increased more than 50% between the date of biopsy and registration, a new baseline MRI is required on a stable or decreasing steroid dosage for at least 3 days even if the previous MRI was within 21 days of registration
For patients who have undergone or will undergo open resection of recurrent or progressive tumor, residual disease following resection is not mandated for eligibility into the study; to best assess the extent of residual disease post-resection, a MRI scan should be done no later than 96 hours in the immediate post-resection period and within 21 days prior to registration; if the 96-hour scan is more than 21 days before registration, the scan needs to be repeated; if the steroid dose is increased more than 50% between the date of imaging and registration, a new baseline MRI is required on a stable or decreasing steroid dosage for at least 3 days
Evidence of tumor progression by MRI or computed tomography (CT) scan following radiation therapy or following the most recent anti-tumor therapy; note: patients who have had surgical treatment at recurrence are eligible if they had a resection with measurable or non-measurable residual disease on postoperative imaging or if there is imaging evidence of disease progression as compared to the first postoperative scan
The presence of at least one lesion that can be accurately assessed at baseline by CT, MRI or plain X-ray and is suitable for repeated assessment. Estimated life expectancy of more than 12 weeks.
Residual disease following resection of recurrent tumor is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, an MRI should be done no later than 96 hours in the immediate postoperative period or at least 4 weeks postoperatively, within 14 days prior to registration; if the \within 96-hour of surgery\ scan is more than 14 days before registration, the scan needs to be repeated
Evidence of metastatic disease on bone scan or MRI/computed tomography (CT)
Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease
Evidence of central nervous system (CNS) hemorrhage on baseline MRI or computed tomography (CT) scan (except for grade 1 hemorrhage that has been stable for at least 3 months)
Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:\r\n* They are > 2 weeks from surgery\r\n* They have recovered from the effects of surgery\r\n* Evaluable or measurable disease following resection of recurrent tumor is mandated for eligibility into the study\r\n* To best assess the extent of residual disease post-operatively, an enhanced CT/MRI should be done no later than 96 hours after surgery or it will need to be done 4-6 weeks post-operatively; if the 96 hour scan is more than 2 weeks from registration, the scan needs to be repeated
A baseline scan should be performed within 14 days prior to registration and on a steroid dosage that has been stable for at least 5 days otherwise a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
Patients must have shown unequivocal evidence for tumor progression by MRI (or CT for patients who cannot tolerate MRI) in comparison to a prior scan; the same type of scan, i.e., MRI (or CT for patients who cannot undergo MRI) must be used throughout the period of protocol treatment for tumor measurement
Residual disease of recurrent glioblastoma is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, a post-operative MRI scan must be performed prior to registration and is recommended to be within 96 hours post-surgery (although 24-48 hours would be optimum). Note: Patients who did have surgery with a post-operative contrast-enhanced scan falling outside the 5-week window prior to registration, must have a repeat MRI scan within 14 days prior to registration.
Implanted metal or metal devices that make a MRI scan prohibitive, history of claustrophobia or other condition that would make a MRI scan prohibitive
MRI (contrast is not required but strongly recommended) of the involved spine within 4 weeks prior to registration to determine the extent of the spine involvement; an MRI is required as it is superior to a CT scan in delineating the spinal cord as well as identifying an epidural or paraspinal soft tissue component; note: if an MRI was done as a screening imaging study for eligibility, the MRI can be used as the required MRI for treatment planning
At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)
Inability to tolerate po; patients who have a computed tomography (CT) scan with contrast dye within 7 days and/or have a pacemaker will be excluded from having a dual energy x-ray absorptiometry (DEXA) scan only
Have had an abdominal imaging test (CT, MRI, or ultrasound) within the past 7 months
All nodules should be persistent at least after three months follow up with 1 dimension (1d)-CT; a reduction up to 15% of the diameter of the largest target nodule from the previous CT scan is allowed
Measurable tumor by CT or MRI
Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (99m-Tc-MDP or Na-18F) within 4 weeks of enrollment.
Eligibility of a perfusion CT target lesion must be confirmed by the ACR Core Lab prior to study enrollment and the T0 perfusion CT scan
Any condition including, metallic implants or cardiac pacemakers that makes the candidate ineligible for MR imaging; (MRI research screening form will be completed prior to each MRI scan)
SUB-STUDY III: Imaging evidence of suspected metastatic disease, including CT, bone scan, MRI, ultrasound or other PET modalities
Evidence of stroke or mass lesion on CT or MRI scan
Three different adult patient groups will be eligible for inclusion in this study: \r\n* Group 1: Adult patients with compelling evidence of primary brain tumor based on clinical and magnetic resonance imaging (MRI) or computed tomography (CT) imaging characteristics that have not yet received surgery, histological diagnosis, or any tumor-directed therapy; such evidence will include: MRI or CT scan-documented mass lesion within the brain, accompanied by anatomically appropriate neurological signs and symptoms, in the absence of a probable competing diagnosis such as brain abscess or primary intracranial hematoma\r\n* Group 2: Newly diagnosed primary malignant brain tumors (World Health Organization [WHO] grade II-IV glial-based tumors) who have not had a complete surgical resection and by contrast MRI or CT have residual tumor >= 1.0 cm in diameter and will be receiving radiotherapy and/or chemotherapy\r\n* Group 3: Patients with probable or possible recurrent primary brain tumor as determined by standard clinical criteria or MRI or CT imaging; the abnormality must be >= 1.0 cm in diameter by contrast MRI or CT or show changes on non-enhancing MRI sequences (T2 or fluid-attenuated inversion recovery [FLAIR])
Visible lesions by either CT, bone imaging, or MRI consistent with disease
Patients who have started radiographic evaluation and underwent CT scan and/or bone scan prior to registration to the study will be able to participate under a late registration provision, provided that the more modern scans (WB/axial MRI and F-18 NaF PET/CT) can be completed within 8 weeks after CT scan and bone scan
Patients undergoing a planning CT scan in the Department of Radiation Oncology with tumor motion assessment - planning 4-dimensional (4D)-CT ordered by the treating radiation oncologist
imaging modalities (bone scan, MRI or CT) OR
Measurable disease on CT scan
No findings of pancreatic disorder as documented by CT or MRI or EUS
Patients for whom the physician is able to identify suitable implantation sites for the anchored transponders on a recent (within the past 8 weeks) CT scan. This will require acquisition of a CT scan if a suitable one is not already available.
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI)\r\n* NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
No lytic lesions on skeletal survey and whole body positron emission tomography (PET)/computed tomography (CT) other than a single lesion associated with solitary bone plasmacytoma
Documentation by positron emission tomography(PET)/computed tomography (CT) scan, CT scan, or magnetic resonance imaging (MRI) that the patient has untreated measurable metastatic disease per RECIST 1.1
Measurable disease >= 1.5 cm seen on computed tomography (CT) scan and fludeoxyglucose F-18 (FDG) avid disease on positron emission tomography (PET) scan
No evidence of metastases based on radiological imaging (computed tomography [CT], MRI or positron emission tomography [PET]/CT including chest abdomen and pelvis)
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
A baseline computed tomography (CT) chest/abdomen/pelvis and bone scan or positron emission tomography (PET)/CT
Measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT (PET/CT fusion); skins lesions can be used if the area is greater than or equal to 2 cm in at least one diameter and photographed with a ruler
Patients must have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan
?1 bone lesion identifiable by radiograph, computed tomography (CT), positron emission tomography - computed tomography (PET-CT), or magnetic resonance imaging (MRI).
Patients who cannot undergo neither MRI nor computed tomography (CT) evaluation/examination
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of at least 1.5 cm in minimum dimension by computed tomography (CT) scan with contrast, as assessed by the site radiologist
Patients with measurable disease defined as at least one of the following:\r\n* For patients with extramedullary disease (EMD) measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm; skin lesions can be used if the area is >= 2 cm in at least one diameter and measured with a ruler\r\n* Plasma cell count >= 0.5 X 10^9/L or 5 percent of the peripheral blood white cells\r\n* Plasma cell count if determined by flow cytometry, >= 200/150,000 events
Absence of lytic bone lesion on X-ray, computed tomography (CT), or positron emission tomography (PET)/CT and not more than 1 lesion on spinal magnetic resonance imaging (MRI) (NOTE: at the discretion of the investigator, PET/CT may replace MRI in patients who have a contraindication to MRI)
Have measurable disease based on defined as at least one lesion that can be accurately measured in at least two dimensions with a spiral computed tomography (CT) scan, positron emission tomography (PET)/CT scan, or magnetic resonance imaging (MRI). Minimum measurement of > 1.5 cm in longest diameter by > 1.0 cm in short axis.
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Patients with systemic T cell lymphoma of any stage and any subtypes; patient must have had at least one standard chemotherapy and measurable disease at the time of enrollment; bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Patients must have systemic cross-sectional imaging (positron emission tomography [PET]/computed tomography [CT] or CT of chest, abdomen, and pelvis) which shows no evidence of metastatic disease
Stage M1\r\n* Metastatic disease can be documented by bone scan or computed tomography (CT) scan or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT or the combination of these tests
Patients who cannot undergo MRI or single-photon emission computed tomography (SPECT)/computed tomography (CT)
Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer
Have measurable disease by computed tomography (CT) or positron emission tomography (PET) scan, with one or more sites of disease >= 1.5 cm in longest dimension
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
Neck computed tomography (CT) and/or neck magnetic resonance imaging (MRI), and whole body positron emission tomography (PET)-CT
Staging computed tomography (CT) chest, abdomen, pelvis (CAP) or positron emission tomography (PET)/CT shows no evidence of metastatic disease
Patients are required to have computed tomography (CT) neck and chest or positron emission tomography (PET)/CT and have no documented evidence of distant metastases
Measurable nodal disease by computed tomography (CT)
Subject who are willing to undergo a bone marrow aspiration and biopsy and computed tomography (CT) scan for disease burden assessment
Patients must have measurable disease, defined as at least one lesion that is > 15 mm (1.5 cm) in the longest axis on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral computed tomography [CT]), positron emission tomography (PET)-CT or magnetic resonance imaging (MRI)
Stage II-IV disease; participant will need measurable disease by computed tomography (CT) or positron emission tomography (PET) scans if enrolled in the dose-expansion cohort
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen/pelvis or CT/positron emission tomography (PET) scans
Patient must have measurable disease > 1.5 cm evidenced by computed tomography (CT) of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT), or computed tomography (CT), of at least 1.5 cm within the last 21 days before the start of IP treatment.
The treated lesion must be within 2 cm of the abdominal gastrointestinal tract (abdominal esophagus to sigmoid colon) on the basis of cross sectional imaging study such as computed tomography (CT), positron emission tomography (PET)/CT, or MRI
Presence of radiographically measurable disease (defined as the presence of a >= 1.0 cm lesion, as measured in the longest dimension by computed tomography [CT] scan or positron emission tomography [PET]/CT scan or magnetic resonance imaging [MRI] scan)
Metastatic breast cancer not amenable to potentially curative surgery; patients must have disease that is measurable and/or non-measurable as defined by RECIST 1.1 criteria (assessed by computed tomography [CT] scan chest/abdomen/pelvis with contrast or fludeoxyglucose [FDG] positron emission tomography [PET]-CT scan obtained within 4 weeks of registration)
Measurable disease that has not been previously irradiated on positron emission tomography-computed tomography (PET-CT) of at least 1.5 cm
Subjects with more than one site of distant metastatic disease (beyond the head and neck) as evidenced by computed tomography (CT) scan or positron emission tomography (PET)/CT or biopsy\r\n* A subject with a single lung nodule (deemed cancerous by PET/CT or biopsy) will not be excluded
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Presence of measurable disease by computed tomography (CT) scan
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and dimensional measurable disease of at least 1.5 cm as documented by radiographic technique (spiral computed tomography [CT] preferred)
Disease status requirement: Measurable disease defined as the presence of ? 1 nodal lesion that measures ? 1.5 cm in a single dimension as assessed by X-ray Computed Tomography (CT) (Positron Emission Tomography (PET/CT), or magnetic resonance imaging [MRI]
Have baseline imaging within 6 weeks of enrollment (computed tomography [CT], magnetic resonance [MR] or positron emission tomography [PET]/CT imaging) and have measurable disease on physical examination or imaging studies; any lesion >= 1.5 cm in long axis dimension is considered measurable
Have measurable nodal disease, including at least 1 disease site measuring 1.5 cm in longest dimension on computed tomography (CT) or fludeoxyglucose (FDG)-positron emission tomography (PET)
Patients must have metabolically active (positron emission tomography [PET] scan positive) measurable disease (defined as lesions greater than 1.5 cm long axis that can be accurately measured in two dimensions by computed tomography [CT])
Subjects must be able to undergo either MRI or computed tomography (CT)
Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more); Note: CT scans remain the standard for evaluation of nodal disease
No distant metastasis by positron emission tomography (PET)/computed tomography (CT); PET/CT will be done at time of simulation in the treatment position
The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib
Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by a diagnostic quality computed tomography (CT) scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
Bone marrow involvement based on computed tomography (CT) or PET scan at screening
History of severe reaction to contrast-enhanced computed tomography (CT) scan
Patients with solid tumors must have measurable or evaluable (for neuroblastoma and Ewing sarcoma) disease. Tumor assessment will be done via computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion. Bone scans (if clinically indicated) should be obtained within ? 4 weeks prior to the start of treatment.
Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) (dedicated CT or the CT portion of a positron emission tomography [PET]/CT) or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of >= 1.5 cm \r\n* NOTE: Skin lesions can be used if the area is >= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
Patients must have measurable disease, defined as at least one lesion that is ? 15 mm (? 1.5 cm) in the longest axis on cross-sectional imaging and measurable in two perpendicular dimensions per spiral computed tomography (CT) scan or positron-emission tomography (PET)-CT scan
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment
Staging computed tomography (CT) scans done prior to enrollment
Pre-operative scans including MRI/computed tomography (CT) neck and, CT chest with contrast; if contrast is contraindicated, staging positron emission tomography (PET) or PET-CT is acceptable although high quality/diagnostic cross-sectional imaging of the head and neck area is recommended
Melanoma cohort only: measurable disease defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT; NOTE: disease that is measurable by physical examination only is not eligible
If remission status < 1 year for NHL, complete remission documented by computed tomography (CT) or positron emission tomography (PET)-CT scan within 3 months of study entry
Disease evaluable by computed tomography (CT) or positron emission tomography (PET) imaging
Patients are preferred to have either a tumor mass amenable to core needle biopsy during the dosimetry phase, or a measurable tumor mass with at least one site of involvement measuring 2.5 cm in largest dimension on computed tomography (CT) imaging for purposes of planar and/or single-photon emission computed tomography (SPECT)/CT tumor dosimetry
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic; laboratory parameters are not acceptable as the only evidence of disease
(B) Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, Computed tomography (CT), or PET-CT
Measurable nodal disease by computed tomography (CT)
Patients must have measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
Bidimensional measurable disease of at least 1.5 cm in the greatest transverse diameter as documented by computed tomography (CT) or positron emission tomography (PET)/CT
Patients must be in complete remission at D60-180 after AHCT as evidenced by computed tomography (CT) scan of the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter\r\nby computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Patients with history of second malignancy are eligible if they have documentation of disease stability, off therapy, based on computed tomography (CT) scan or other measures for the 6 months prior to entry in core
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Participants must have had PET-computed tomography (CT) for restaging after salvage therapy and before ASCT
Subject has evidence of pre-existing idiopathic pulmonary fibrosis on computed tomography (CT) scan at baseline
Patients with measurable disease; patients with non-measurable but evaluable disease may be eligible after discussion with the principal investigator (PI); baseline measurements and evaluations must be obtained within 6 weeks of registration to the study; abnormal positron emission tomography (PET)/computed tomography (CT) scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)
Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-CT (PET-CT) OR
Measurable disease for phase IIa portion only \r\n* Lymphoma (includes CTCL patients who are without evidence of the disease in the skin): computed tomography (CT) or positron emission tomography (PET)/CT by modified Cheson criteria with incorporation of PET\r\n* CTCL: modified severity weighted assessment (mSWAT) > 0, or absolute Sezary count >= 1000 cells/uL
Radiographic evidence (computed tomography [CT], magnetic resonance [MR], or positron emission tomography [PET] CT) consistent with osseous metastatic disease on CT, MR, or PET CT obtained within 4 weeks of treatment will be used for pre-study treatment delivery; the gross tumor volume (GTV) of the target lesions will be determined from this radiographic study and must be =< 250 cubic centimeters\r\n* NOTE: patient is still eligible if a diagnostic image set is not available within 4 weeks of treatment if the patient will undergo a kilo voltage CT (kVCT) simulation in the Department of Radiation Oncology with contouring directly onto this image set
Chemosensitive disease as defined by at least a partial response to salvage therapy by PET/computed tomography (CT) criteria
Measurable disease: lesions that can be accurately measured in at least two dimensions as >= 1.0 x 1.0 cm by computerized tomography (CT), PET/CT (positron emission tomography/CT), or magnetic resonance imaging (MRI)
For patients with solid malignancies and lymphoma, radiographically detectable (either fludeoxyglucose-positron emission tomography [PET], computed tomography [CT] scan/magnetic resonance imaging [MRI] or bone scan) or measurable disease will be required; measurable disease is defined as at least one measurable lesion >= 10 mm on CT scan (15 mm for nodal lesions)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) or the CT portion of the positron emission tomography (PET)/CT: must have at least one lesion that has a single diameter of >= 2 cm or tumor cells in the blood >= 5 x 10^9/L; skin lesions can be used if the area is >= 2 cm in at least one diameter and photographed with a ruler
All lung lesions must be visible on computed tomography (CT) imaging
>= 1 measurable disease site on computed tomography (CT) scan or positron emission tomography (PET) (> 1.5 cm in longest dimension); (in select cases, for example extremity lesions, a magnetic resonance imaging [MRI] may be substituted)
Female patients with inoperable tumors or women with stage 4 disease diagnosed on computed tomography (CT), positron emission tomography (PET), PET/CT or bone scan
Histologically or cytologically confirmed pancreatic adenocarcinoma that has metastatic disease measurable by computed tomography (CT), magnetic resonance imaging (MRI), or (positron emission tomography (PET)
Measurable disease by computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) with at least one target lesion measuring 1.5 cm or larger
Tumor is not clearly shown on a computed tomography (CT) scan
Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT)
A subject with metastatic CRPC must have bone metastases accessible for biopsy by computed tomography (CT) guidance
Patients must have measurable disease on the 3D planning computed tomography (CT)
Measurable disease by computed tomograph (CT)/ and/or positron-emission tomography CT (PET-CT)
Patients should have measurable disease defined as a minimum of one tumor measuring >= 10 mm on computed tomography (CT) scans
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with computed tomography (CT) scan, positron emission tomography (PET) CT, or magnetic resonance imaging (MRI) exam
Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans
Measurable or assessable disease defined as at least one of the following:            \r\n* A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by computed tomography (CT) portion of positron emission tomography (PET)/CT scan, CT scan, or magnetic resonance imaging (MRI)\r\n* Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
Fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
Measurable disease (at least 1 lesion of >= 1.5 cm in diameter) as detected by computed tomography (CT) or the CT images of the positron emission tomography (PET)/CT
Computed tomography (CT) of the neck to confirm staging
Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism
Scheduled for low dose computed tomography (CT) screening for lung cancer
Presence of cT1 renal mass by diagnostic computed tomography (CT) assessment
After completion of radiotherapy, within the last 12 months, a positron emission tomography (PET)/computed tomography (CT) or contrast-enhanced CT scan must be performed within 8 weeks of registration demonstrating no evidence of disease or loco-regional recurrence
Referred for computed tomography (CT) guided biopsy of lung lesion
Measurable disease >= 1.5 cm as measured on positron emission tomography (PET)-computed tomography (CT) scan
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm (>= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 28 days prior to start of protocol therapy; the CT from a combined positron emission tomography (PET)/CT may be used if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease
Measurable disease (or nonmeasurable bone-only disease) assessed by computed tomography (CT) or positron emission tomography (PET)/CT, performed as part of standard of care, at the discretion of the attending oncologist
Willing and able to undergo low dose computed tomography (CT) scan, as determined by radiology team, or has had a lung cancer screen within 30 days of enrollment into this protocol.
Bone lesions (1 or more osteolytic lesions on low-dose whole body computed tomography [LDCT], positron-emission tomography with computed tomography [PET-CT] or CT)
Have a measurable lesion in the pelvis or abdomen, at a minimum of 0.5 cm in diameter on standard of care pre-operative imaging studies (computed tomography [CT], magnetic resonance imaging [MRI] or positron emission tomography [PET] scan)
Subject must have been referred for a clinically indicated PET-computed tomography (CT)
Patients who have a history of serious adverse events related to a previous MRI or PET/computed tomography (CT)
Inability to undergo or cooperate with PET/computed tomography (CT) scan (e.g., claustrophobia)
No clinical evidence of nodal disease (N1-N3) as assessed by CT and/or positron emission tomography (PET)/CT
Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan
Has measurable disease defined as ?1 lesion that can be accurately measured in ?2 dimensions with spiral computed tomography (CT) scan or combined CT/positron emission tomography (PET) scan. Minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis.
Appropriate for protocol entry based upon the following minimum diagnostic workup:\r\n* History/physical examination including examination for encephalopathy, ascites, weight, height, and blood pressure within 14 days prior to study entry\r\n* Assessment by radiation oncologist and medical oncologist or hepatologist who specializes in treatment of HCC within 28 days prior to study entry\r\n* Pre-randomization scan (REQUIRED for all patients): Within 28 days prior to study entry, CT scan chest/abdomen/pelvis or positron emission tomography (PET) CT chest/abdomen/pelvis with multiphasic liver CT or multiphasic liver magnetic resonance (MR) scan (MRI of abdomen and pelvis with contrast with CT chest) is permitted
Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization. Confirmation of disease-free status will be assessed by an independent central radiologic review of imaging data.
Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease
Investigations, including chest X-ray or computed tomography (CT) chest, bone scan (with radiographs of suspicious areas) and abdominal ultrasound or liver scan or CT abdomen have been performed between the first histologic diagnosis and the time of registration\r\n* Chest X-ray, 2 view (or chest CT, or positron emission tomography [PET]/CT) is required only if clinically indicated or recommended by National Comprehensive Cancer Network (NCCN) guidelines\r\n* Bone scans (with x-rays of abnormal areas) are required only if indicated or recommended by NCCN guidelines\r\n* Abdominal imaging is required only if clinically indicated or recommended by NCCN guidelines
Clinical stage: T2N1, T3N0, T3N1\r\n* N2 disease is to be estimated as four or more lymph nodes that are >= 10 mm\r\n* Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, computed tomography (CT) or positron emission tomography (PET)/CT scan of the chest/abdomen/pelvis and either a pelvic magnetic resonance imaging (MRI) or an ultrasound (endorectal ultrasound [ERUS]); if a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis
Baseline chest computed tomography (CT) must be performed within 1 month (30 days) of randomization to ensure no evidence of disease; if clinically indicated, additional imaging studies must be performed to rule out metastatic disease
Contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the neck, chest, abdomen and pelvis; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)
The patient must have the following assessments done =< 8 weeks prior to randomization:\r\n* Examination by a head and neck surgeon\r\n* Chest x-ray (or chest computed tomography [CT] scan or CT/positron emission tomography [PET] of the chest or magnetic resonance imaging [MRI]) to rule out distant metastatic disease
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/magnetic resonance imaging [MRI] of abdomen/pelvis, bone scintigraphy or NaF PET/CT)
Patients must have no evidence of extrapelvic disease; complete workup staging should be performed prior to initiation of therapy to rule-out presence of metastatic disease; this should include: computed tomography (CT) scan of the thorax with IV contrast, as well as a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness; if the patient is unable to tolerate contrast, then magnetic resonance imaging (MRI) with IV gadolinium should be performed; a chest x-ray should be done first, and if abnormal, then a CT scan of the chest should be done
Any pT-stage based on American Joint Committee on Cancer 7th edition eligible; study entry will be based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to step 1 registration\r\n* Negative distant metastatic workup: \r\n** A computed tomography (CT) scan of the abdomen and pelvis (with contrast [CT without contrast is permitted if the patient is not a candidate for contrast, i.e., renal function or allergy]) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to step 1 registration; (Please note: Lymph nodes will be considered negative (NO)if they are =< 1.5 cm short axis);\r\n** Bone scan within 120 days prior to step 1 registration; (please note: a sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute and if the bone scan is suspicious, a plain x-ray, CT scan, NaF PET/CT and/or MRI must be obtained to rule out metastasis)
Contrast-enhanced computed tomography (CT) scans of the chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head and neck is required only if the patient has a head/neck primary; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; if skin lesions are being followed as measurable disease, photograph with a ruler included and physician measurements, must be kept in the patient’s chart as source documentation; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) with no evidence of distant metastasis, based upon the following minimum diagnostic workup:\r\n* History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration\r\n* Evaluation of tumor extent with one of the following combinations required within 28 days prior to registration:\r\n** Magnetic resonance imaging (MRI) of the nasopharynx and neck; or computed tomography (CT) of the nasopharynx and neck with =< 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement). \r\n** MRI of the nasopharynx and positron emission tomography (PET)/CT (with contrast) of the neck\r\n*** Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous slices with contrast and be read by a radiologist\r\n* To rule out distant metastasis, patients must undergo the following imaging within 28 days prior to registration:\r\n** A CT scan with contrast of the chest and abdomen (required), and the pelvis (optional), or a total body PET/CT scan (non-contrast PET/CT is acceptable)\r\n** A bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to registration\r\n* Clinical grade computed tomography (CT) scans of the chest, abdomen, and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT within 60 days prior to study registration
Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis demonstrating no evidence of nodal involvement or metastatic disease (magnetic resonance imaging [MRI] or computed tomography [CT] scan) within 90 days prior to registration; patients with T1 disease must have re-resection confirming =< T1 disease within 90 days prior to registration
Patient must have computed tomography (CT) chest/abdomen/pelvis with contrast or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT scan performed within 28 days prior to step 1 registration
Patient must have a CT of chest/abdomen with contrast or FDG-PET/CT scan within 28 days prior to step 2 registration; patients must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors
Patient must have a CT of chest/abdomen/pelvis with contrast or FDG-PET/CT scan within 28 days prior to step 3 registration; patient must not have evidence of progression per RECIST 1.1 or modified RECIST for pleural tumors
Patients with evidence of extramedullary disease at diagnosis will have computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis to obtain baseline values within 28 days prior to registration
The following imaging workup to document metastases within 45 days prior to study registration are required: CT scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body (at least skullbase to midthigh) positron emission tomography (PET)/CT
No evidence of metastatic cancer on imaging including a bone scan and computed tomography (CT) scan of chest/abdomen/pelvis
Patients with evidence of extramedullary disease at diagnosis will have computed tomography (CT) scan of the chest, abdomen and pelvis to obtain baseline values within 28 days prior to registration
Chest imaging =< 3 months of enrollment, including computed tomography (CT)-scan or chest x-ray
Systemic staging of the chest/abdomen (abd), pelvis is required for study entry; body fluid will be assessed based on this study
Positron emission tomography (PET)/CT scan including neck, chest, abdomen, pelvis within 4 weeks of study enrollment documenting the absence of distant metastases
Patients with N2 or N3 nodal disease or T3 primary disease must undergo liver and bone imaging (as described in 4.1.13 and 4.1.14) within 28 days prior to randomization, irrespective of baseline lab results, and studies must not demonstrate metastatic disease. Chest imaging with chest x-ray PA and Lateral, CT of the chest, or PET-CT must also be performed.
Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and liver) must be performed within 28 days prior to initiation of Induction Phase treatment.
Metastatic disease identified via radiographic assessment by computed tomography (CT) scans of the chest, abdomen, pelvis, and nuclear bone scan; magnetic resonance imaging (MRI) may be used if deemed necessary by the investigator; more specifically, patients must have at least one of the following at time of study enrollment:\r\n* Any visceral metastases identified by CT scans or MRI\r\n* Site(s) of bony metastasis identified by nuclear bone scan, MRI, and/or CT scan\r\n* Lymph node based disease not considered to be within a single radiation therapy port (e.g. at or above the aortic bifurcation)
Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization
Patient has one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if patient is allergic to CT contrast media) per RECIST 1.1. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease must be performed within 14 days prior to randomization. Qualifying scans performed as part of standard of care prior to patient signature of the study informed consent will be acceptable as baseline scanning as long as scanning is performed < 14 days prior to randomization.
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan, and CT scan or x-ray of the chest within 56 days prior to registration; if the alkaline phosphatase is > 1.5 x upper limit of normal (ULN), there is a presence of suspicious bone pain, or if there is other clinical suspicion of bone metastases, a whole body bone scan is required within 56 days prior to registration
Prior to chemotherapy +/- or thoracic radiotherapy, patients must be defined as limited-stage or extensive-stage SCLC after clinical staging evaluation involving the following:\r\n* History/physical examination;\r\n* Computed tomography (CT) of the chest and abdomen with contrast (does not have to be done if the patient has had a positron emission tomography (PET)/CT scan prior to initiating chemotherapy or thoracic radiotherapy)\r\n* MRI of the brain with contrast or diagnostic head CT with contrast\r\n* For patients without evidence of extensive-stage SCLC on chest and abdomen CT and brain MRI or head CT, a PET/CT or bone scan is required to confirm limited-stage SCLC
Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
Stage III A or B disease, including no distant metastases- based on following diagnostic workup:\r\n* History/physical examination prior to registration\r\n* Computed tomography (CT) scan of the chest or positron emission tomography (PET) scan within 28 days of study entry\r\n* CT scan of abdomen or magnetic resonance imaging (MRI) of abdomen or PET scan within 28 days of study entry\r\n* An MRI of the brain or head CT scan with contrast within 28 days of study entry\r\n* Total body PET scan within 28 days of study entry\r\n* Mediastinoscopies are highly recommended
Subjects must be free of visible disease on imaging (computed tomography [CT], positron emission tomography CT [PETCT] or magnetic resonance imaging [MRI]) evaluating chest, abdomen, and pelvis within 28 days of enrollment on the study
Patients with muscle-invasive (i.e. T2, T3, T4), locally advanced non-resectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 28 days prior to study registration; the required radiographic imaging includes:\r\n* Abdomen/Pelvis – computed tomography (CT) scan\r\n* Chest – chest x-ray or CT scan
Has visceral metastases with >= 3 lung and/or liver metastases or individual lesion >= 2 cm, as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis within the last 8 weeks prior to randomization
Clinical stage T1N0, T2N0, T3N0; high risk T1 and low risk T3 stage patients are also allowed. Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon, computed tomography (CT) chest/abdomen/pelvis or positron-emission tomography (PET)/CT along with pelvic MRI and endoscopic rectal ultrasound (ERUS). If a pelvic MRI is performed, it is acceptable to perform CT of the chest/abdomen, omitting CT imaging of the pelvis.
Locoregional lymph node metastases are permitted but patients with distant metastases are ineligible; imaging to evaluate for distant metastases should consist of a minimum of computed tomography (CT)/magnetic resonance imaging (MRI) of abdomen/pelvis or CT urogram and a chest x-ray (CXR) or CT chest; patients for which there is clinical suspicion or symptoms of bone metastasis should have a bone scan completed to rule out metastatic disease prior to enrollment on study
To be eligible for randomization, patients must: \r\n* Meet all the inclusion criteria;\r\n* Have no progression of disease after 6-12 weeks of osimertinib per RECIST 1.1. (To assess for progressive disease patients must have the following imaging: \r\n** Either a positron emission tomography (PET)/computed tomography (CT) scan or a CT scan of the chest/abdomen/pelvis (or CT chest) ** A CT scan or a magnetic resonance imaging (MRI) of the brain);\r\n* Have target lesions (lesions that will be treated with LCT if the patient is randomized to that arm). Patients that have a complete response (CR) to front-line osimertinib (e.g. no visible disease to target) will continue to be followed for progression on study but will not be randomized
Must be tumor-free as assessed by the Investigator and validated by either computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain and chest, abdomen, and pelvis and a bone scan ?28 days from randomization.
Absence of baseline imaging studies (CT abdomen/pelvis and Chest x-ray minimum) both prior to beginning chemotherapy and following chemotherapy
Locally advanced or metastatic disease not amenable to surgery with curative intent with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator based on an assessment of all known disease sites by computerized tomography (CT) scan or magnetic resonance imaging (MRI) of chest/abdomen/pelvis within 28 days before the first dose of cabozantinib. In patients with intravenous (IV) contrast allergy or borderline renal function, CT without IV contrast or 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) CT may be used as clinically indicated.
Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration;\r\n* Computed tomography (CT) imaging of the chest, abdomen and pelvis within 28 days prior to registration documenting disease consistent with FIGO stage Ill or IV disease (patients who cannot receive contrast may instead undergo magnetic resonance imaging [MRI] of abdomen and pelvis along with non-contrast chest CT);
Pretreatment computed tomography (CT) chest /abdomen /pelvis within 28 days of protocol enrollment
Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging; computed tomography (CT) or positron emission tomography (PET)/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration; for patients with history of brain metastases, brain magnetic resonance imaging (MRI) or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration; diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging
Measurable disease on computed tomography (CT) scan of thorax, abdomen, and pelvis per RECIST v1.1 criteria
Patients with locally advanced unresectable or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 28 days prior to study registration; the required radiographic imaging includes:\r\n* Abdomen/Pelvis – computed tomography (CT) scan\r\n* Chest – chest x-ray or CT scan
Patients will undergo CT imaging of the chest, abdomen, and pelvis to evaluate lung and liver metastases within 30 days of registration; for patients who cannot tolerate CT contrast or have hepatic steatosis that reduces the sensitivity of CT, MRI of the liver will be performed
Surgically resectable (T2N0, T3N0, Tany with node positivity, M0), as determined by endoscopic ultrasound (EUS) and the following minimum diagnostic work-up:\r\n* Whole-body PET/computed tomography (CT) (PET/CT of skull base to mid-thigh is acceptable)\r\n* EUS =< 21 days prior to registration\r\n* NOTE: Patients may have regional adenopathy including para-esophageal, gastric, gastrohepatic and celiac nodes; if celiac adenopathy is present, it must be < 2 cm\r\n* NOTE: If patient unable to have PET/CT then CT chest/abdomen/pelvis with contrast (preferred) or MRI chest/abdomen/pelvis with contrast
No evidence of metastases other than regional lymphadenopathy as assessed by imaging of the chest, abdomen and pelvis with CT of the chest and CT or MRI of the abdomen; regional lymph nodes, per 7th edition American Joint Committee on Cancer (AJCC) staging manual (2010) for kidney cancer, include the following positions: renal hilar, precaval, paracaval, retrocaval, interaortocaval, paraaortic, preaortic, and retroaortic
No evidence of metastasis on staging computed tomography (CT) scans of the chest, abdomen and pelvis
No distant metastases, based on the following workup within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the pelvis or computed tomography (CT) abdomen/pelvis (A/P)\r\n* Bone scan or sodium fluoride positron emission tomography (PET), that if suspicious has MRI or plain X-rays to rule out bone metastasis
Radiographically measurable or clinically evaluable disease by computed tomography (CT) scan of chest/abdomen/pelvis with and without contrast =< 28 days prior to registration
No evidence of metastatic disease based on imaging of the chest, abdomen and pelvis
Computed tomography of the chest, abdomen, and pelvis (CT CAP) and bone scan performed within 30 days prior to study entry and does not demonstrate metastatic disease
Within 60 days of registration: patients must have fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)-CT scan (or CT chest/abdomen/pelvis with IV contrast), and magnetic resonance imaging (MRI) brain with IV contrast (preferred) or CT scan of the brain with contrast; non-contrast MRI scans of the chest/abdomen/pelvis or brain are permitted for workup if patient has allergy to CT contrast or renal insufficiency
Patients must have a CT of chest, abdomen, and pelvis with PET within 28 days of enrollment; patients with evidence of lymphadenopathy in the neck must have a dedicated CT of neck
Patients must have a computed tomography (CT) (preferred) or magnetic resonance imaging (MRI) scan of the chest, abdomen, and pelvis within 28 days of enrollment
Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within 14 days of registration
Patients with no evidence of distant metastatic disease based on CT scan of the chest/abdomen/pelvis; diagnostic laparoscopy, is recommended but not required and is at the discretion of the surgical oncologist; peri-pancreatic or regional lymphadenopathy that does not preclude a surgical resection is acceptable
Participants must have no clinical, radiographic, or laboratory evidence of cancer dissemination to the peritoneal cavity, chest cavity, or spread via hematogenous dissemination; computed tomography (CT) or positron emission tomography (PET)/CT of the chest, abdomen and pelvis must have been obtained within 10 weeks of study entry; there must be no measurable (macroscopic) disease within the radiation target volume following hysterectomy and lymphadenectomy
Baseline imaging in the form of CT chest, abdomen, pelvis with oral and intravenous contrast within 28 days of study entry; for patients with a contrast allergy, choice of alternative body imaging will be at the discretion of the investigator or his designee; magnetic resonance imaging (MRI) of the brain is only needed if clinically indicated
Patients must have no evidence of metastatic disease based on routine imaging (computed tomography [CT] or magnetic resonance imaging [MRI] of the chest/abdomen/pelvis, bone scan, etc.)
No distant metastases, based upon the following minimum diagnostic workup:\r\n* History and physical exam including a detailed description of the location, size and stage of the sarcoma, within 10 weeks prior to study entry\r\n* CT or magnetic resonance imaging (MRI) with contrast of the abdomen and pelvis within 8 weeks prior to study entry; the maximal dimension of the primary tumor will be measured in CT and MRI images; and\r\n* CT scan of the chest within 8 weeks prior to study entry
Participants with multifocal disease, lymph node or distant metastases; Note: multiple pulmonary nodules < 8 mm without a histological diagnosis detected incidentally in a non-screening CT scan may not be a basis for study exclusion because of the sensitivity/specificity of the CT scans of the chest/abdomen/pelvis
CT, magnetic resonance imaging (MRI), or PET/CT imaging of the chest, abdomen, and pelvic regions within 42 days prior to registration (for stage I patients, posterior-anterior [PA] and lateral chest x-ray is sufficient for chest imaging)
MRI/CT of brain within 42 days of lymphodepletion; CT scan of chest/abdomen/pelvis or PET/CT within 30 days of lymphodepletion; Exception: patients randomized to receive dendritic cells may have an MRI of the brain within 30 days of lymphodepletion (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)
Patients must have imaging of the chest/abdomen/pelvis, preferably with a computed tomography (CT) scan, and a bone scan within 4 weeks prior to randomization; (NOTE: if a patient is unable to receive CT contrast, a magnetic resonance imaging [MRI] of the abdomen/pelvis and non-contrast chest CT should be performed; positron emission tomography/computed tomography [PET/CT] is not an acceptable alternative)
No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT, abdominal CT or MRI)
BLADDER: Patients may not have evidence of metastatic disease on baseline computed tomography (CT) or magnetic imaging resonance of the chest, abdomen, or pelvis
Patients must have a FDG-PET-computed tomography (CT) of chest, abdomen, and pelvis within 28 days of enrollment
Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 28 days prior to randomization; Note: Distant clinical staging to exclude patients with overt metastatic disease is determined by:\r\n* Chest: CT scan (preferred); chest x-ray posterioranterior (PA) and lateral (acceptable); or positron emission tomography (PET) scan (acceptable)\r\n* Abdomen: CT scan with IV contrast (preferred); or MRI (acceptable)\r\n* Pelvis: MRI (preferred) or CT scan with IV contrast (acceptable)\r\n** (It is recommended that the same imaging tests that are performed before randomization be used at follow-up time points; Note: CT scans of the abdomen and pelvis must be performed with IV contrast)
Pathologic stage III or IV HNSCC, including no distant metastases, based on the following minimum diagnostic workup:\r\n* General history/physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration\r\n* Examination by an ear nose and throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation\r\n* Pre-op Imaging of the head and neck: a neck computerized tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via transfer of images and data (TRIAD); the report is to be uploaded into Rave\r\n* Chest imaging with either a CT scan (with or without contrast) or CT/PET (with or without contrast) that includes the chest within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration;\r\n* Examination by an ear nose throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation\r\n* Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave\r\n* Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement
Metastatic disease as demonstrated by bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI) of the pelvis, or chest x-ray
The patient must be free of unresectable metastatic disease within 4 weeks prior to the surgery being performed with the intention to remove all melanoma; this pre-surgery baseline assessment must be documented by complete physical examination and imaging studies; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) in conjunction with a brain magnetic resonance imaging (MRI) (or head CT if brain MRI is contraindicated); if a PET/CT scan cannot be done, a CT of the neck, chest, abdomen, and pelvis should be performed
All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan (with or without brain) and brain magnetic resonance imaging (MRI) or CT (if MRI is contraindicated); if PET-CT cannot be done, CT of neck, chest, abdomen, and pelvis should be done\r\n* If for some reason a CT cannot be done, an MRI may be done instead; any other imaging studies if performed (eg, bone scan) must show no evidence of disease
Negative metastatic workup with bone scan and computed tomography (CT) abdomen/pelvis, within 6 months of study treatment, if indicated by PSA > 10
Computed tomography (CT) chest, abdomen, and pelvis performed
Clinical stage T1-T2, N1-N2b or T3, N0-N2b (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) including no distant metastases based on the following diagnostic workup:\r\n* General history and physical examination within 56 days prior to registration\r\n* Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 70 days prior to registration\r\n* One of the following combinations of imaging is required within 56 days prior to registration:\r\n** A CT scan of the neck (with contrast) and a chest CT scan (with or without contrast)\r\n** Or a magnetic resonance imaging (MRI) of the neck (with contrast) and a chest CT scan (with or without contrast)\r\n** Or a CT scan of neck (with contrast) and a PET/CT of neck and chest (with or without contrast)\r\n** Or an MRI of the neck (with contrast) and a PET/CT of neck and chest (with or without contrast)\r\n*** Note: a CT scan of neck and/or a PET/CT performed for the purpose of radiation planning may serve as both staging and planning tools
Computerized tomography (CT) urogram or magnetic resonance imaging (MRI) urogram; if urogram protocol not available or contrast allergy/poor renal function preclude such imaging, then noncontrast CT or MRI of the abdomen/pelvis within 45 days of study entry will suffice
No distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration\r\n* Whole body fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT within 30 days prior to registration\r\n** NOTE: if whole-body FDG-PET/CT is not performed, CT of the chest and CT (or MRI) of abdomen and pelvis must be obtained (imaging of abdomen and pelvis need not be repeated if already included in pancreas protocol study)
Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen or pelvis
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 45 days prior to registration\r\n* Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging; this may be performed pre- or post-surgery within 90 days prior to registration; imaging performed post-operatively should show no evidence of residual disease; any evidence of malignancy identified on pre-operative imaging should have been completely resected surgically prior to protocol treatment; chest CT or chest x-ray must be performed within 90 days prior to registration (unless a PET-CT has been performed)
Appropriate diagnostic imaging performed including a CT or MRI of the brain and CTs of the thorax, abdomen, pelvis; CT of the neck and imaging of the extremities may be indicated depending on the clinical presentation must be complete and satisfactory within 30 days of initiation of chemotherapy
Histologically documented adenocarcinoma of the prostate with metastatic disease as evidenced by soft tissue (e.g. lymphoid) and/or bony metastases on baseline computed tomography (CT) scan of the abdomen and pelvis and/or bone scan
CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless medically contraindicated) within 6 weeks prior to registration
No evidence of systemic non-Hodgkin lymphoma as demonstrated by a computed tomography (CT) scan of the chest, abdomen, and pelvis within 6 weeks prior to registration (note: bone marrow biopsy is not required for registration but must be obtained prior to start of treatment)
Patients will have a baseline computed tomography (CT) chest, abdomen and pelvis within 30 days of registration
The following minimum diagnostic workup is required:\r\n* History/physical examination within 2 weeks prior to registration\r\n* Imaging of neck and brain (computed tomography [CT] scan or magnetic resonance imaging [MRI]) and chest/abdominal imaging (chest x-ray or chest CT scan, or full body positron emission tomography [PET]/CT are acceptable) within 4 weeks prior to registration\r\n* Note: the CT scan of the neck must be done with contrast or if an MRI is done, with gadolinium; therefore, the CT portion of a full body PET/CT has to be a high resolution CT to be acceptable for eligibility\r\n* Abdominal imaging must cover the liver and adrenal glands; therefore, separate imaging is not required if these areas are covered by a chest CT scan\r\n* Electrocardiogram within 10 days prior to registration
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within 56 days prior to registration; if alkaline phosphatase is above the treating institution’s upper limit of normal (ULN), presence of suspicious bone pain, or if other clinical suspicion, a whole body bone scan is required within 56 days prior to registration
All patients must have disease-free status documented by a complete physical examination and imaging studies within 42 days prior to registration; imaging studies must include a total body positron emission tomography (PET)-computed tomography (CT) scan that is of diagnostic quality (with or without brain) or a CT of the chest, abdomen and pelvis; for patients with melanoma arising from the head and neck, dedicated neck imaging (CT with IV contrast or PET-CT through the region) is required; if the patient has had unknown primary with disease in the axilla, neck imaging is required to assure region is clear of cancer; CT imaging should be done with intravenous contrast if there are no contraindications for it; any other clinically-indicated imaging studies if performed (e.g. bone scan) must show no evidence of disease
Patients must not have any evidence of residual or metastatic renal cell cancer on computed tomography (CT) scan of the chest, abdomen, and pelvis, all with oral and intravenous (IV) contrast after nephrectomy and within a maximum of 28 days prior to registration; a magnetic resonance imaging (MRI) scan of the abdomen/pelvis with gadolinium and a non-contrast CT of the chest is an acceptable imaging alternative; non-contrast CT of the chest/abdomen/pelvis should only be performed if, in the opinion of the investigator, it is in the best medical interest of the patient to not receive IV contrast of any form; NOTE: positron emission tomography (PET)/CT is not an acceptable imaging alternative; patients who display subcentimeter pulmonary nodules (by CT scan) that are non-specific and considered unlikely to represent metastatic disease by the treating investigator will be considered eligible
All patients must have no evidence of persistent or metastatic disease as documented by a post-resection computed tomography (CT) of the chest/abdomen/pelvis or by CT chest + magnetic resonance imaging (MRI) abdomen/pelvis; the post-resection imaging studies should be performed within 4 weeks of registration on study
Abdominal/pelvic computed tomography (CT) scan with contrast is preferred; abdominal CT alone is acceptable only if insurance restrictions are experienced; chest CT/x-ray (CT of chest preferred) within 31 days of registration on study (or within 31 days prior to day 1 of chemo post-surgery for those patients having started chemotherapy prior to first step registration); patients allergic to intravenous (IV) contrast can have magnetic resonance imaging (MRI) of the abdomen/pelvis instead
Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases, based upon the following minimum diagnostic workup:\r\n* General history and physical examination by a radiation oncologist and/or medical oncologist within 8 weeks prior to registration\r\n* Examination by an ear, nose and throat (ENT) or head & neck surgeon, within 8 weeks prior to registration; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is recommended but not required\r\n* Chest x-ray (at a minimum) or chest computed tomography (CT) scan (with or without contrast) or CT/positron emission tomography (PET) of chest (with or without contrast) within 8 weeks prior to registration
Imaging (positron emission tomography/computed tomography (PET/CT) scan, CT scan, or magnetic resonance imaging (MRI)) of chest, abdomen, and pelvis must be performed within 90 days prior to randomization and must demonstrate no evidence of metastatic disease. If findings noted in imaging study reports are equivocal, the determination of whether or not the findings represent metastatic disease will be at the investigator's discretion.
Patients must have metastatic disease. Baseline imaging of chest, abdomen and pelvis (CT or MRI) within 21 days prior to initiation of protocol therapy is required.
Participants must have histologically or cytologically confirmed invasive squamous, basaloid, or cloacogenic carcinoma of the anal canal; pathology must be reviewed by the treating institution; patients must be clinically staged as T stage 1-4 and N0-N3 stage, based upon the following minimum diagnostic work-up:\r\n* History/physical examination within 42 days prior to registration\r\n* Anal examination with mandatory biopsy and any of the following: colonoscopy, sigmoidoscopy, rigid proctoscopy, or anoscopy; digital rectal examination (performed at the discretion of the treating physician) with documentation of primary anal lesion size, distance from the anal verge, and anal tone is also recommended\r\n* Groin examination with documentation of any groin adenopathy and lymphadenopathy (location: right vs. left, medial vs. lateral, mobile vs. fixed, and size)\r\n* A biopsy is not needed for pathologically enlarged or clinically suspicious inguinal, perirectal, or pelvic lymph nodes on examination, computed tomography (CT) scan, or positron emission tomography (PET)/CT and will be considered clinically positive\r\n* No evidence of distant metastatic disease as determined by CT scan with contrast, or PET/CT scan of the chest within 42 days prior to registration and CT scan with contrast, magnetic resonance imaging (MRI), or PET/CT of the abdomen and pelvis within 42 days prior to registration
The following imaging workup to document metastases within 45 days prior to study registration: \r\n* Computed tomography (CT) scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT
To rule out metastatic disease, patients must have the following tests:\r\n* Bone scan within 60 days prior to registration\r\n* Computed tomography (CT) of abdomen/pelvis within 60 days prior to registration
Negative radiographic metastatic work-up including whole body radionuclide bone scan, computed tomography (CT), and/or magnetic resonance (MR) scan of the pelvis and abdomen, and chest x-ray; patients with suspicious areas on conventional imaging studies may be included if they are biopsy negative
Contrast enhanced CT of the chest and upper abdomen
Evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within six weeks of study entry; distant nodal disease is allowed if it is in the radiation port
Baseline bone scan, chest x-ray and computed tomography (CT)/magnetic resonance imaging (MRI) of abdomen/pelvis demonstrating no metastatic disease
A bone scan and a CT or MRI abdomen/pelvis and chest x-ray (CXR) or chest CT scan, will have been performed within 12 weeks of treatment start; radiographic assessments will be selected by the attending physician as clinically indicated
Prior radiation to the chest or abdomen
There should be no evidence of metastatic disease on imaging of the chest, abdomen, and pelvis; this imaging should be either a contrast-enhanced computed tomography (CT) scan, or a contrast-enhanced magnetic resonance imaging (MRI) scan; positron emission tomography (PET) scans alone will not be adequate alternatives; there should be no evidence of occult metastatic disease in the abdomen, confirmed by laparoscopic examination
Clinically determined to be clinically staged (American Joint Committee on Cancer [AJCC] 7th edition [ed.]) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup within 90 days prior to registration:\r\n* Colonoscopy\r\n* History/physical examination (including medication history screen for contraindications)\r\n* Contrast-enhanced imaging of the abdomen and pelvis either by computed tomography (CT), magnetic resonance imaging (MRI), or whole body positron emission tomography (PET)-CT (preferred)\r\n* Chest x-ray (or CT) of the chest to exclude distant metastases (except for those who have had whole body PET-CT per above bullet point)\r\n* Transrectal ultrasound (TRUS) or MRI for T staging
Metastatic disease as evidenced by both lymphadenopathy and bony metastases or just bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen and pelvis within 28 days of registration; chest imaging is only required if clinically indicated or if there is known disease in the chest
Visceral metastases as assessed by chest, abdominal or pelvic computed tomography (CT) (or other imaging modality)
For all patients a bone scan must be performed within 60 days prior to registration for tumor assessment; computed tomography (CT) scans (abdomen and pelvis) and chest x-ray are optional, but must be repeated if used for disease assessment; for late induction registrations, tumor assessment imaging showing metastatic disease must be available prior to start of androgen deprivation therapy
Patients must have non-metastatic (M0) disease, as defined by a lack of metastases seen on computed tomography (CT) scan of the chest/abdomen/pelvis and whole-body radionuclide 99Tc (technetium-99) bone scan, (or sodium fluoride positron emission tomography [PET] scan) taken within 3 months of study entry
Imaging with positron emission tomography (PET) scan, computed tomography (CT) scan of the abdomen and pelvis, and/or magnetic resonance imaging (MRI) of the abdomen and pelvis must be performed and negative for metastatic disease within 12 weeks of enrollment
Evidence of metastatic disease as evidenced by a computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis and/or whole body bone scan (WBS); to be done prior to treatment start and up to 4 months prior to radical prostatectomy date
No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese); all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese)
No evidence of metastatic disease on imaging by whole body bone scan and computerized tomography (CT) or Magnetic Resonance Imaging (MRI) of the abdomen/pelvis within 6 weeks prior to randomization
Participants must not have metastatic disease; pre-operative chest CT scan is required within 10 weeks prior to registration; patients with overt evidence of lung metastatic disease are excluded from the study; however, because of the sensitivity/specificity of the chest CT, small incidental lesions without a histologic diagnosis may not be a basis for study exclusion
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (computed tomography [CT] of abdomen/pelvis, bone scintigraphy)
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within six weeks of study entry; all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal [abd] MRI with gadolinium and/or manganese)
Appropriate stage for protocol entry, based upon the following minimum diagnostic workup:\r\n* History and physical examination, including a complete list of current medications\r\n* Chest x-ray (posteroanterior [PA] and lateral views)\r\n* Abdominal/pelvic computed tomography (CT) scan\r\n* Brain magnetic resonance imaging (MRI) if clinically indicated\r\n* Bone scan if clinically indicated
Subjects must have baseline (screening/baseline) radiographic images, (e.g. brain, chest, abdomen, pelvis, and bone scans with specific imaging tests to be determined by the attending physician) within 6 weeks of initiation of ipilimumab
Patients must not have evidence of bone metastases or lymph node involvement as determined by bone scan or computed tomography (CT) scan of the abdomen and pelvis within 4 weeks of study entry; Note: NaF-PET/CT scan information will NOT be used to determine evidence of metastases for eligibility purposes or for defining disease progression
Patients must have no evidence of visceral or nodal metastatic disease proximal to the common iliac bifurcation on 2 view chest x-ray or computed tomography (CT) of the chest and abdominal-pelvic imaging with computerized tomography or magnetic resonance imaging (MRI) of the abdomen and pelvis; chest x-ray or CT of the chest and CT or MRI of the abdomen and pelvis must be obtained within 56 days prior to registration; positron emission tomography (PET)/CT may be used as an alternative to CT or MRI or to resolve possible areas of metastases seen on cross sectional imaging
Metastatic disease or regional lymph node involvement. Chest CT will be mandatory prior to enrollment to evaluate for the presence of metastatic disease. Pulmonary nodule(s) < 5 mm without a histological diagnosis may not be the basis for study exclusion given the lack of specificity of chest CT. If pulmonary nodule(s) > 5 mm are noted on chest CT but appear stable relative to prior chest imaging of at least 6 months duration, then this is permitted.
Negative CT scans of the chest, abdomen, and pelvis within 6 months prior to enrollment to rule out possibility of metastases;
Patients must have the following within 4 weeks prior to registration:\r\n* Computed tomography (CT) chest with intravenous (IV) and oral agent\r\n* CT pelvis/abdomen with IV and oral agent\r\n* MRI brain with gadolinium\r\n* For patients with known bone metastases, elevated alkaline phosphatase or symptoms raising suspicion of bone metastases, a baseline bone scan is required
Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT imaging of the chest, abdomen, and pelvic regions within 60 days prior to registration (for stage I patients, posteroanterior [PA] and lateral chest x-ray is sufficient for chest imaging)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination =< 45 days prior to registration;\r\n* Computed tomography (CT) chest, CT or magnetic resonance imaging (MRI) or positron emission tomography (PET)-CT that includes abdomen and pelvis should be performed for initial radiological staging; this may be performed pre- or post-surgery =< 90 days prior to registration except in patients getting postoperative adjuvant chemotherapy, who will require CT, MRI or PET-CT including the chest and abdomen and pelvis no more than 30 days prior to registration; imaging performed postoperatively should show no evidence of residual disease
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration \r\n* Assessment by medical oncologist who specializes in treatment of IHC within 30 days of registration \r\n* Pre-randomization scan (REQUIRED for all patients): computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan within 30 days prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen and pelvis is permitted
Have had a CT or MRI scan (chest, abdomen, pelvis and other suspected sites as applicable) to determine eligibility for randomization within 4 weeks prior to randomization (hereafter referred to as the \eligibility scan\)
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including recording of pulse, blood pressure (BP), weight, and body surface area, within 45 days prior to registration\r\n* Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to mid-thighs) within 30 days prior to registration; PET/CT must be negative for distant metastasis\r\n* CT scan with contrast of the chest and upper abdomen to include liver and adrenals (unless medically contraindicated) within 30 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with contrast, if MRI medically contraindicated) within 30 days prior to registration
No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes on staging scans (computed tomography [CT] chest/abdomen/pelvis and bone scan or positron emission tomography [PET] scan)
No evidence of metastatic disease as determined by chest computed tomography (CT) scan, and abdominal CT scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese); all patients must be staged with a physical exam, chest CT, abdominal CT with intravenous contrast (or abdominal MRI with gadolinium and/or manganese)
All patients must have their disease status documented by a complete physical examination and imaging studies within 4 weeks prior to the first dose of study drug. Imaging studies must include computerized tomography (CT) scan of neck, chest, abdomen, pelvis, and all known sites of resected disease in the setting of Stage IIIb/c or Stage IV disease, and brain magnetic resonance imaging ([MRI], brain CT allowable if MRI is contraindicated).
Patients must have a diagnostic quality contrast computed tomography (CT) scan of the chest, abdomen and pelvis OR baseline positron emission tomography (PET)-CT scan performed within 28 days prior to registration
Stage clinical T1 N0 M0 or T2 N0 M0 as per American Joint Committee on Cancer (AJCC) Staging system 7th edition, based on the following criteria:\r\n* Chest computed tomography (CT) with upper abdomen to include the liver and adrenal glands with intravenous (IV) contrast (unless medically contraindicated) within 2 months of registration\r\n* Participants must have measurable disease, defined as >= 5 mm on a diagnostic CT scan with slice thickness of no more than 2.5 mm\r\n* Positron emission tomography (PET)/CT scan including neck, chest, abdomen, pelvis within 2 months of study enrollment characterizing the primary tumor and documenting the absence of nodal and distant metastasis\r\n* Brain magnetic resonance imaging (MRI) with gadolinium within 2 months of study enrollment demonstrating the absence of brain metastasis; if an MRI is medically contraindicated or if the patient refuses, a head CT with IV contrast is acceptable
Post-operative computed tomography (CT) scan of the chest, abdomen, and pelvis =< 30 days prior to registration demonstrating no evidence of residual or recurrent malignancy
No evidence of cancer within 28 days prior to start of study treatment; this should be determined by imaging of the chest, abdomen and pelvis by computed tomography (CT) and/or magnetic resonance imaging (MRI); staging of the chest using chest x-ray in lieu of CT and/or MRI should not be used for this purpose
CT scan chest, abdomen and pelvis or positron emission tomography (PET)/CT scan (diagnostic quality CT) performed within 28 days of study registration; for disease outside the brain, tumors must be > 10 mm by CT scan
Radiographic evidence of radiation pneumonitis on a computed tomography (CT) scan of the chest with or without contrast
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head and neck is required only if the patient has a head/neck primary; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; if skin lesions are being followed as measurable disease, photograph with a ruler included and physician measurements, must be kept in the patients chart as source documentation; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
Chest radiograph or computed tomography (CT) scan within =< 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
Uncontrolled infections, defined as positive blood cultures within 72 hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within 14 days of registration
No evidence of any lymph node spread or distant metastases as determined by positron emission tomography (PET) computed tomography (CT) imaging within 16 weeks of enrollment; alternatively, for those without PET CT capability, a magnetic resonance imaging (MRI) or CT of the abdomen and pelvis and a chest x-ray confirming no evidence of metastatic disease is acceptable
Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, chest x-ray is required; CT imaging of the chest or PET/CT is acceptable
Patients must have had a contrast-enhanced computerized tomographic (CT) scan of the chest and abdomen within 2 months of study entry and be willing to have a follow up scan within 2 months of the completion of the retreat
Subjects must have had a negative bone scan, and computed tomography (CT) of abdomen and pelvis within 16 weeks prior to registration; additional forms of imaging (Prostascint scan, magnetic resonance imaging [MRI]) may be substituted for a CT scan of the abdomen and pelvis if clinically indicated
Conventional chest abdomen and pelvis CT images demonstrating recurrent tumor must be submitted within 21 days from acquisition to the American College of Radiology (ACR) Core Lab
Patients scheduled and approved for contrast enhanced CT that includes imaging of the abdomen and pelvis following the Department of Radiology standard of care protocol
Subjects must have a computed tomography (CT) scan of the chest within 8 weeks of surgery
Patients will have undergone or have agreed to undergo standard of care CT of the chest, abdomen, and pelvis; 18F-FSPG PET imaging will be performed as investigational studies
Have undergone or agree to undergo standard of care imaging for ovarian cancer with CT chest, abdomen, and pelvis
Completed staging evaluation with bone scan as well as CT or magnetic resonance imaging (MRI) of the abdomen and pelvis at least 45 days prior to study enrollment
Patients with endobronchial involvement seen on chest CT
Baseline imaging to rule out distant metastatic disease (technetium Tc 99m [99mTc] bone scan, sodium fluoride [NaF] PET, total body MRI, or computed tomography [CT] chest/abdomen/pelvis)
Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
Had a chest computed tomography (CT) scan within the past 18 months prior to enrollment
Computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis within 28 days of Cycle 1 Day 1.
Part C: Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)
Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry
In the expansion cohort: subjects must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; bone lesions are not considered measurable by definition
Bony metastatic lesions must be =< 8 cm in maximum dimension and evaluable on either a computed tomography (CT) or magnetic resonance imaging (MRI) scan; metastatic lesions in the spine must involve =< 3 contiguous vertebral bodies
At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version 1.1
Have undergone magnetic resonance imaging (MRI) for MB, a computerized tomography (CT) / metaiodobenzylguanidine (MIBG) scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month prior to first dose of study treatment
Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Post-operative computed tomography (CT) myelogram or magnetic resonance imaging (MRI) perfusion with evidence of separation of tumor and the spinal cord
The subject has had an assessment of all known non-CNS disease sites e.g., by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
At least 1 measurable lesion as defined by RECIST 1.1 on imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI])
All patients must have measurable disease documented by computed tomography (CT), magnetic resonance imaging (MRI), or nonmeasurable disease documented by physical exam within 28 days prior to registration
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 28 days before the first dose of cabozantinib
Hepatocellular carcinoma (HCC) diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs 5 per the American College of Radiology [ACR’s] LIRADs criteria) by computed tomography (CT) or magnetic resonance imaging (MRI)
Has 1 or more discrete malignant lesions that are amenable to ?2 separate biopsies guided by one of the following modalities: visual inspection, ultrasound guidance, or cross sectional image guidance (computed tomography/magnetic resonance imaging [CT/MRI]).
Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v1.1.
Must be able to tolerate computed tomography (CT) and/or magnetic resonance imaging (MRI) with contrast
Metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
Tumor thickness is 4 mm or less (measured clinically and/or by computed tomography [CT] or magnetic resonance imaging [MRI] scan)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 that can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan
Individuals with distant metastases or clinically or pathologically involved lymph nodes are ineligible; if suspected, they must be ruled out by computed tomography (CT), pelvic magnetic resonance imaging (MRI), or bone scan within 365 days of study entry
Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1
Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
At least one lesion that can be accurately assessed at baseline by computed tomography (TC), magnetic resonance imaging (MRI) or X-ray, that is suitable for repeated measurement, OR
Evidence of metastatic disease on imaging studies (computed tomography [CT] and/or bone scan)
Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography [CT] scan or magnetic resonance imaging [MRI])
Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
Must be found to have locally advanced unresectable disease following standard chemotherapy and/or (+/-) radiotherapy as demonstrated with computed tomography (CT)/magnetic resonance imaging (MRI) and surgical evaluation
Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on computed tomography [CT] scan and/or magnetic resonance imaging [MRI] of the abdomen and pelvis)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI).
Magnetic resonance imaging (MRI) pelvis, computed tomography (CT) pelvic, or bone scan for a PSA >= 0.2 ngs/ml may be done, based on the physician preference
Six or more metastases on diagnostic or treatment planning imaging, which include either computed tomography (CT) or magnetic resonance (MR) imaging.
Metastatic disease documented by at least one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI)
Evidence of metastasis by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histologic confirmation
Subject has at least 1 measurable lesion per RECIST v1.1 criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
Metastatic disease evident on computed tomography (CT) or magnetic resonance imaging (MRI) staging scans
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Patient must have recent imaging (computed tomography [CT] or magnetic resonance imaging [MRI], as appropriate) within 4 weeks of trial enrollment, demonstrating measurable disease as defined by RECIST 1.1.
Radiographic confirmation of oligometastatic diagnosis via bone scan validated by either computed tomography (CT) scan or magnetic resonance imaging (MRI) within the past 90 days
Unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or have documented recurrent glioma on diagnostic biopsy
Patients with a parenchymal brain lesion thought to be consistent with active lymphoma on screening computed tomography/magnetic resonance imaging (CT/MRI); of note, patients with cerebral spinal fluid (CSF) involvement alone are not excluded
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans).
Evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable FDG-avid lesions on PET)
Patients must have imaging (magnetic resonance imaging [MRI] or computed tomography [CT] abdomen liver protocol) confirmed hepatocellular carcinoma. Patients cannot have metastatic HCC
Measurable disease, even after resection of applicable lesion for TIL harvest; defined as >= 1 lesion that is >= 10 mm in one dimension by computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers on clinical exam
Measurable disease by RECIST v1.1 criteria (tumor >= 1 cm in longest diameter on axial image on computed tomography (CT) or magnetic resonance imaging (MRI) and/or lymph node(s) >= 1.5 cm in short axis on CT or magnetic resonance imaging [MRI]) on baseline imaging
Evidence of metastatic disease to the bone seen on most recent bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Has measurable disease as defined by RECIST 1.12 on computed tomography (CT) or magnetic resonance imaging (MRI) and as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Gross disease apparent on imaging (magnetic resonance imaging [MRI] or computed tomography [CT])
Patients must have at least one lesion that is not within a previously radiated field and that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scans per RECIST version 1.1; bone lesions are not considered measurable
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
Active disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
>= 1 evaluable site of disease measuring >= 1.5 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) as measured per Response Evaluation Criteria in Solid Tumors (RECIST)
Bone disease documented by either: a positive bone scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI); or biopsy proven bony metastases
At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.
COHORT 2 (ON PROGRESSION OF SORAFEINIB): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on computed tomography/magnetic resonance imaging (CT/MRI); prior surgery or local therapy within 4 weeks prior to cycle 1 day 1, with the exception of palliative radiation therapy to the bone
Evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computed tomography (CT) scan; subjects with resolving hemorrhage changes, punctuate hemorrhage, or hemosiderin are eligible
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Clinical stage T3 or less as demonstrated by computed tomography (CT)/magnetic resonance imaging (MRI) will be selected as the prostate is resectable
Patients must have potentially resectable pancreatic carcinoma and have agreed to undergo surgical resection at Monroe Dunaway (MD) Anderson Cancer Center if operable; they will have undergone staging (physical examination, contrast enhanced computed tomography [CT] or magnetic resonance imaging [MRI] [if CT contraindicated] to determine resectability)
Unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes
No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to registration
Patients with evidence of an acute intracranial or intratumoral hemorrhage on computed tomography (CT) or magnetic resonance imaging (MRI) are not eligible (patients with evidence of resolving hemorrhage will be eligible)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
All patients positive for invasion must have imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI]) documenting normal upper urinary tracts and absence of locally advanced bladder cancer within 60 days prior to study registration
Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
Patients must be willing to undergo a radiologic scan (computed tomography [CT] or magnetic resonance imaging [MRI], depending on organ involved) after last drug dose and prior to minimally-invasive surgery
At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib.
At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI]) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion >= 10 mm in longest diameter
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans)
Has staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within 4 weeks prior to treatment initiation
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated), and if the patients with CNS metastases are not taking prednisone > 10 mg or equivalent daily
Patients must have measurable disease, by computed tomography (CT) or magnetic resonance imaging (MRI) per modified RECIST criteria for mesothelioma; radiographic tumor assessment must be performed within 28 days prior to the first treatment
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)
No evidence of > grade 1 active CNS hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
Localized spine metastasis from the cervical (C)1 to lumbar (L)5 levels with documented epidural cord compression by a screening imaging study (magnetic resonance imaging [MRI] or computed tomography [CT] myelogram); site may have a maximal involvement of 2 contiguous vertebral bodies; patients with other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible
Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria; the criteria specifies computed tomography (CT) or magnetic resonance imaging (MRI) intense arterial uptake followed by “washout” of contrast in the venous-delayed phases; any atypical lesions must be confirmed by biopsy
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])
Patient must have measurable disease\r\n* Tumor size at least >= 5 cm in the longest diameter as measured by computed tomography (CT) scan or magnetic resonance imaging (MRI) for which radiation is feasible
Evidence of metastatic disease: minimum imaging required Computed tomography scan (CT) / Magnetic Resonance Imaging (MRI) and Whole Body Bone Scan (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
Adult patients with locally advanced or recurrent orbital or periorbital BCCA, or a medial canthal BCCA that threatens the lacrimal drainage system, as noted by clinical exam, clinical photography, computed tomography (CT) or magnetic resonance imaging (MRI) and positive biopsy, and who do not have a contraindication to either surgical or vismodegib treatment\r\n* Treating physician to assess whether the patient is a candidate for vismodegib treatment
Participants must have evaluable or measurable disease based on RECIST 1.1 using computed tomography (CT)/magnetic resonance imaging (MRI).
Clinically confirmed brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI) criteria; if there is evidence of extra-cranial metastatic disease, it is preferable if that the lesions be pathologically confirmed and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility
Patients may not be on systemic steroids within 4 weeks of enrolling on study with the exception of physiologic replacement doses (for instance in the case of adrenal insufficiency) or steroid premedication for baseline magnetic resonance imaging (MRI) and/or computed tomography (CT) in the case of subjects with known contrast dye allergies
Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance imaging [MRI] findings)
Known leptomeningeal disease or evidence of prior or current metastatic brain disease (routine screening with central nervous system [CNS] imaging studies [computed tomography (CT) or magnetic resonance imaging (MRI)] is required only if clinically indicated)
Must have presence of an enhancing solid renal mass =< 3.0 cm on computed tomography (CT) or magnetic resonance imaging (MRI)
Diagnostic imaging magnetic resonance imaging (MRI) and/or computed tomography (CT) of the area to be treated within 8 weeks of any treatment; baseline bone marrow biopsy and bone scan (with 99m-Tc-diphosphonate or metaiodobenzylguanidine [MIBG] scan [131I-MIBG or 123I-MIBG]) from time of original diagnosis is required
Clinically negative lymph nodes as established by imaging (pelvic ± abdominal computed tomography [CT] or magnetic resonance imaging [MRI]), (but not by nodal sampling, or dissection) within 90 days prior to registration
The subject has had an assessment of all known disease sites e.g, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Pancreas protocol computed tomography (CT) and/or magnetic resonance imaging (MRI) if required for further clarification of disease tissue planes within 4 weeks of registration
The subject has evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computerized tomography (CT) scan; subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible
Radiographic evidence of metastatic disease; computed tomography (CT) and bone scan must be performed with 21 days (+ 7 days) of registration; magnetic resonance imaging (MRI) of brain can be performed within 6 months prior to registration
Participants must have histologically or radiological evidence of stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Local, locally advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> 1.5 cm)
Contrast computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain negative for central nervous system metastases within 30 days of treatment
Magnetic resonance imaging (MRI) with gadolinium should be obtained within 21 days prior to beginning treatment; patients without measurable disease are eligible; participants must be able to undergo MRIs (computed tomography scans [CTs] are not allowed for response assessment on study)
Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).
Measurable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI)
At least one measurable viable tumor in the liver, ?1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)
Tumor volume occupies less than 50% of liver by volume as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) scan within 4 weeks of treatment
Evidence of distant metastasis; (determined by computed tomography [CT] scan, magnetic resonance imaging [MRI], and/or bone scan prior to the simulation appointment; imaging results from University of Pennsylvania Health System [UPHS] will supersede results from similar scans from an outside facility)
Patients must have an magnetic resonance imaging (MRI) or computed tomography (CT) of the head showing no central nervous system (CNS) metastases within 6 weeks of study entry
Must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI)
Confirmed presence of hepatocellular carcinoma indicated on computed tomography, magnetic resonance, or other imaging techniques within 3 months prior to screening
Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology.
Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)
High-quality cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) performed within 4 weeks prior to enrollment
No evidence of metastatic disease or nodal disease as determined by radionuclide bone scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological lymph nodes must be less than 20 mm in the short (transverse) axis.
At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
Must have measurable disease per RECIST 1.1 as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). a. Lesion/s deemed accessible to biopsy for both before and on-treatment biopsies.
Clinical T1N0M0 (=< 7 cm) renal mass as measured on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
? 5 metastases on conventional imaging with computed tomography (CT)/magnetic resonance imaging (MRI) of the abdomen/pelvis and whole body bone scan
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT]).
All patients must have measurable disease by imaging defined as tumor that can be measured >= 10 mm with multiparametric magnetic resonance imaging (MRI) (primary modality of imaging) or computed tomography (CT) (as an alternative) or >= 10 mm by caliper on physical examination
Measurable or evaluable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version (v)1.1
Patients must have localized disease with a primary tumor >= 5 cm by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by computed tomography (CT) or magnetic resonance imaging (MRI) scan, analysis of cerebrospinal fluid or neurological exam; patients with primary glioblastoma multiforme are excluded
Have been more than 1 month and less than 3 months after the completion of planned adjuvant chemotherapy and no definitive evidence of recurrent disease on screening imaging (computed tomography [CT] or magnetic resonance imaging [MRI]); if adjuvant treatment is not planned, then patients must be more than 1 month and less than 3 months after resection of their pancreas cancer
Computed tomography (CT) or magnetic resonance imaging (MRI) within 14 days prior to start of study therapy
Assessable disease with a positive bone scan and/or measurable disease on computed tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and pelvis
Must have measurable disease by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan; measurable disease is not necessary for inclusion
Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging (MRI) or PET imaging including contrast agents
Known contraindication to enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scan
Histologically confirmed cancer with measurable or evaluable brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI); MRI is preferred, but a CT scan is acceptable for patients that are unable to have an MRI
Unresectable by radiographic criteria (pancreas protocol computed tomography [CT] or magnetic resonance imaging [MRI]) or exploration within 30 days prior to registration
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
Patients will only be eligible for this trial if they have disease with tumor measurable on the computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 criteria.
Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
Any lesion invading or having encasement ? 180 degrees around the wall of a major blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the abdomen and chest; required only if aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or ALP is ?2 x ULN
>= 90% surgical resection of recurrent GBM confirmed by central radiology review by magnetic resonance imaging (MRI) with or without gadolinium per institutional guidelines; a computed tomography (CT) scan is allowable in place of MRI only in situations where an MRI is contraindicated (e.g., patient has a heart pacemaker, metallic devices in the eye, brain or spine, severe claustrophobia)
Radiological or clinical evidence (bone scan, computerized tomography [CT], and magnetic resonance Imaging [MRI]) of recurrence or progression within 30 days before randomization
Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1.
Measurable disease defined per RECIST v. 1.1, or bone-only disease must have a lytic or mixed lytic blastic lesion that can be accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Individuals with bone-only disease and blastic-only metastases are not eligible
Subject has one or more tumors measurable by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; magnetic resonance imaging (MRI) is acceptable if a CT scan is contraindicated
Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments
Has progression and measurable disease in the brain by magnetic resonance imaging (MRI) or computed tomography (CT)
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan
Bi-dimensionally measurable disease on cross sectional imaging by X-ray Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Known leptomeningeal involvement by lymphoma or current metastatic brain disease; routine screening with central nervous system (CNS) imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated
Patients with stage IV malignancy (non-mesothelioma) must have had a brain scan (magnetic resonance imaging [MRI] or computed tomography [CT] with contrast) showing no evidence of disease progression within 8 weeks of study enrollment
Complete clinical remission is defined as cancer antigen (CA)-125 within normal limits, examination and computed tomography (CT) or magnetic resonance imaging (MRI) without objective evidence of disease (non specific abnormalities are permitted on radiologic imaging)
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) that is accessible to biopsy
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 25 weeks prior to registration at very high risk of recurrence as determined by 2 or more of the following combinations:\r\n* cT3a/b\r\n* PSA >= 20\r\n* Gleason score 8-10\r\n* >= 33% core involvement\r\n* OR any patient with pelvic lymph node involvement >= 1 cm as determined by pelvic computed tomography (CT) or magnetic resonance imaging (MRI) imaging will meet eligibility criteria for enrollment
Evidence of lymph node or bone metastasis by magnetic resonance imaging (MRI)/computed tomography (CT), bone scan, or biopsy (N1Mx or NxM1)
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of study inclusion
World Health Organization (WHO) grade IV glioma with definitive resection prior to consent, with residual radiographic contrast enhancing disease on the post-operative computed tomography (CT) or magnetic resonance imaging (MRI) of < 1 cm in maximal diameter in any axial plane
The ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) based volume estimation of the patient’s prostate gland should be =< 80 grams\r\n* For patients with prostate size > 60 grams cytoreduction therapy with ADT is recommended
The subject has evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computed tomography (CT) scan; subjects with resolving hemorrhage, punctate hemorrhage, or hemosiderin are eligible
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain must be performed preoperatively and postoperatively (preferably within 96 hours of surgery), prior to the initiation of radiotherapy
Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician)
Metastatic diseases measurable or evaluable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to RECIST 1.1 criteria; locally recurrent disease that is not amenable to potentially curative surgery or radiation therapy is also allowed; lesions must be >= 10 mm in size; recurrent or metastatic disease within a prior radiation field is acceptable as long as the disease has progressed in the radiation field by RECIST criteria
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =< 28 days of study registration negative for disease recurrence
Evidence of metastatic disease by radiographic imaging (bone scan or other nodal or visceral lesions on computed tomography [CT] or magnetic resonance imaging [MRI])
Evidence of metastatic disease on previous bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Subject has measurable disease by radiographic techniques (computerized tomography [CT] or magnetic resonance imaging [MRI]);
Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (HCC) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of HCC by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT])
Presence of existing lytic bone lesions either by skeletal X-ray, computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
The patient must have post-operative contrast enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) unless only biopsy performed (in which case post-operative imaging is not routinely obtained; in these patients, the preoperative study will serve as baseline
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT), magnetic resonance imaging (MRI); if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
Prostate volume (by ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI] measurement) < 50 cc at time of enrollment
Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed < 30 days prior to registration) and complete neck exam from the skull base to the clavicles; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI); the primary tumor should be cT1 or T2 and cervical nodes cN1, N2a, or N2b based on clinical or radiographic criteria
Unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) with and without contrast and with perfusion (or computed tomography [CT] if MRI is contraindicated); the scan must be performed within 14 days of starting treatment
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Metastatic disease documented by one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI), or
Participants must have histologically or/and radiologically confirmed advanced hepatocellular carcinoma (HCC); radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)
Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria
Local, locally-advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) evidence of hemorrhage deemed significant by the treating physician (> grade 1); subjects with history of central nervous system (CNS) hemorrhage are not eligible
Radiographic evidence of spinal metastasis is required and may be obtained from radionuclide bone scans, computed tomography imaging, and magnetic resonance imaging; other studies may be used with principal investigator approval, but plain radiograph (X-ray) alone is not sufficient
Documented evidence of M1 disease by American Joint Committee on Cancer (AJCC) staging by bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI)
Metastatic disease on imaging (e.g., bone scan, computed tomography [CT], magnetic resonance imaging [MRI]); patients whose disease spread is limited to regional pelvic lymph nodes are not eligible; if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan; for leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable
If patients have small-volume disease the current study will be restricted to patients with minimal ascites not causing abdominal distention/mesenteric thickening or not requiring paracentesis, or lesions =< 5 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI) at baseline
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
Patients with known contraindication to magnetic resonance imaging (MRI), such as cardiac pacemaker, shrapnel, or ocular foreign body; however, head computed tomography (CT) with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant’s CNS lesions are clearly measurable on the head CT
A brain scan should be performed within 14 days prior to registration and steroid dosing should be stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/computed tomography (CT) is required; the same type of scan, i.e., magnetic resonance imaging (MRI) or CT must be used throughout the period of protocol treatment for tumor measurement
Primary disease > 7.5 cm in largest diameter as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
Treated (surgery, radiation therapy) but not clinically and radiographically stable 3 weeks after local therapy(as assessed by contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]), OR
Maximum tumor dimension of =< 6 cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography [CT], magnetic resonance imaging [MRI] or PET/CT) and considered amenable for radiation therapy (RT)
Inability to have neither a magnetic resonance imaging (MRI) nor a computed tomography (CT) scan; patients with a pacemaker must undergo CT instead of MRI to be eligible
Prostate size as determined on magnetic resonance imaging (MRI) to be < 90 cc; prostate size can be determined on computed tomography (CT) scan if MRI is not available
At least 1 lesion (measurable by RECIST v1.1) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment;
Diagnosis of HCC by biopsy-proven pathologic diagnosis or by clinical criteria as defined below: \r\n* Clinical criteria to be met if patient has a history of cirrhosis or chronic hepatitis B infection:\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by magnetic resonance imaging (MRI) or triple-phase computed tomography (CT) scan\r\n** Alpha-fetoprotein (AFP) of any value\r\n* Clinical criteria to be met if patient has no history of cirrhosis or chronic hepatitis B infection\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by MRI or triple-phase CT scan\r\n** And AFP > 20 mg/dL
No evidence of metastatic disease on physical exam, computed tomography (CT)/magnetic resonance imaging (MRI)/chest x-ray (CXR), and bone scan within 4 weeks prior to randomization
Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease; if no histologic confirmation, then the metastases or recurrence will require documentation by a 2nd radiographic procedure (eg. PET/computed tomography [CT] scan or magnetic resonance imaging [MRI] in addition to the CT scan); if the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required
Patients must have at least 1 evaluable lesion. Lesions must be evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
At least 1 node ? 2 cm on computed tomography (CT) or magnetic resonance imaging (MRI) or
Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma and they have evaluable or measurable disease by other (radiographic, magnetic resonance imaging [MRI], computed tomography [CT], lytic measurable lesion on x-ray,) means
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
Presence of metastatic disease (M1) as assessed by computed tomography/ magnetic resonance imaging (CT/MRI) and/or whole-body radionuclide bone scan.
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Hypersplenism documented by imaging study (ultrasound [US] or computed tomography [CT])
Patients with metastatic disease, target lesion must be measurable using computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have a patent portal vein as documented by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound
Imaging, a combination of at least two of the following (computed tomography [CT], magnetic resonance imaging [MRI], endoscopic ultrasound [EUS]) staging the pancreatic mass as “locally advanced”
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan.
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic, previously irradiated lesions are eligible provided participant is >/=4 weeks beyond completion of cranial irradiation and >/=3 weeks off of corticosteroid therapy
Patient with known but adequately treated brain metastases and without central nervous system (CNS) disease progression as determined by computed tomography (CT) or magnetic resonance imaging (MRI) imaging within 4 weeks of the first dose of study drug
Subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI)
Documented metastatic disease on bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI)
Appropriate diagnosis for protocol entry, based upon the following minimal diagnostic work-up:\r\n* History/physical examination within 8 weeks prior to registration and:\r\n* Suspicion of metastatic cancer to the vertebrae or multiple myeloma with a focus in a vertebral body(ies) and;  \r\n* The lesion must be identifiable with radiologic evidence (x-ray, bone scan, computed tomography [CT] scan, magnetic resonance imaging [MRI])
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not available) of the brain must be performed within 14 days prior to study entry
Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography (CT) or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last cancer therapy within 6 months prior to randomization.
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Brain lesion(s), if still present, must be confirmed stable (i.e., no increase in lesion size) for >= 6 weeks prior to randomization (stability must be confirmed with two consecutive magnetic resonance image (MRI) or computed tomography (CT) scans with contrast, AND
Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan
Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
Pre-operative computed tomography (CT)/magnetic resonance imaging (MRI) abdomen and pelvis within 90 days
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans
Subject has no contraindication for computed tomography (CT) and/or magnetic resonance imaging (MRI) during screening and is able to complete a screening examination; CT and/or MRI within 6 months of screening is required
Patients must have a diagnostic quality magnetic resonance imaging (MRI) of the brain or if contraindicated then contrast computed tomography (CT) scan of the head performed within 28 days prior to registration
Subjects must have at least one lesion that is not within a previously radiated field that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; if the subject’s only evaluable disease is within a previously radiated field, it must have demonstrated progression since the time of radiation
Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1
At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Subjects must have measurable disease by computed tomography (CT) scans or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to first dose of study drug
Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation
Patients with known bone metastases, with evidence of corticol bone damage/lytric lesions/blastic lesions on standard imaging studies (computed tomography [CT]/magnetic resonance [MR])
Radiographic (X-ray, or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
Metastatic bone disease with metastatic disease previously confirmed by prior biopsy; or Metastatic bone disease previously confirmed on imaging [e.g. computed tomography (CT) or magnetic resonance imaging (MRI)] with known (biopsied) primary disease (primary bone cancer is excluded)
Patients must have achieved a documented complete response to treatment based on normal cancer antigen (CA)-125 (per the institution’s upper limit of normal) and computed tomography (CT) scan or magnetic resonance imaging (MRI) with contrast (i.e. there must be no clinical evidence of persistent or recurrent disease based on CA-125 and CT scan or MRI with contrast)
Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception: If deemed clinically significant, then liver imaging must be available within previous 6 months (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI]) showing no evidence of hepatocellular carcinoma
Advanced chronic pancreatitis as determined by the following criteria: EUS score greater than 6, calcifications in combination with atrophy and/or dilation of >= 5 mm, or evidence of advanced chronic pancreatitis by computed tomography (CT) or magnetic resonance imaging (MRI) results in the past 12 months
Confirmed diagnosis of liver cirrhosis assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging [MRI]), or liver biopsy
Confirmed diagnosis of liver cirrhosis (Child-Pugh A or B) assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging (MRI), or liver biopsy
Subjects with bone dominant disease with at least 2 skeletal metastases identified at baseline by bone scintigraphy and confirmed by computed tomography (CT)/magnetic resonance imaging (MRI).
Patients with untreated focal liver observations on liver ultrasound or multiphase contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) performed as part of clinical standard of care within 4 weeks before patient enrollment
Undergone standard of care conventional imaging (computed tomography [CT] and/or magnetic resonance [MR]; bone scan and/or sodium fluoride [NaF] PET)
Have at least one kidney lesion identified but incompletely characterized on a non-contrasted ultrasound (US), computed tomography (CT), or magnetic resonance (MR) exam for which the patient’s provider recommends follow-up studies or further evaluation with an additional imaging tests.
PATIENT: Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT] or ultrasound [US]) in the 24 hours prior to the research US exam
For patients with organ confined renal tumors to be enrolled, the renal mass must be >= 1 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage T1a-T4 (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney
GROUPS 1, 2, AND 3: Group 2 participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
Measurable or evaluable disease, lesions that have not been previously radiated, with clinically indicated imaging evaluation performed within 4 weeks prior to study entry (computed tomography [CT], magnetic resonance imaging [MRI], fluorodeoxyglucose [FDG]-PET or bone scan); patients requiring concurrent radiation treatment are not eligible unless additional lesions that are not being irradiated and are assessable for targeting are present
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Primary or recurrent/metastatic lesion size >= 1.5 cm as determined by imaging studies (ultrasonography, mammography, computed tomography [CT] or magnetic resonance imaging [MRI]) or physical examination
Patients with at least 1 measurable tumor lesion as assessed by Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST 1.1.
Patients who received anti-tumor therapy after histopathologic transformation to glioblastoma must have shown unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan if MRI is contraindicated)
Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT], of US) in the 24 hours prior to the research US exam
Be scheduled for contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) to monitoring of RCC recurrence as part of their 8, 12, 18, 24, or 36 month CT/MRI follow up
Presence of at least one measurable or detectable metastasis as defined by bone scintigraphy, computed tomography (CT) scan appearance (magnetic resonance imaging [MRI] if indicated), or plain x-ray appearance
Patients must have radiographic evidence of upper tract urothelial cancer by computed tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in order to undergo this procedure
The lesion shows intratumoral arterial phase enhancement on contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
Tumor =< 4 cm maximum diameter, including clinical stage IA and selected IB by positron emission therapy (PET)/computed tomography (CT) scan of the chest and upper abdomen performed within 90 days prior to randomization
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met
Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan
Patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note positron emission tomography [PET]/CT scan may be used as an alternative imaging technique)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination by a radiation oncologist (and a surgeon if surgery is planned) within 30 days prior to registration\r\n* Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least diagnostic quality computed tomography (CT) chest through the adrenals or positron emission tomography (PET)/CT, within 30 days prior to registration.
Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup:\r\n* History/physical examination within 8 weeks prior to registration\r\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable
Patients must have undergone radical hysterectomy (open, laparoscopically or robotic) and staging including pelvic node sampling or dissection for cervical carcinoma within 70 days prior to study entry (NOTE: if the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a positron emission tomography [PET]-computed tomography [CT] is recommended, but not required; a negative pre or post-operative PET scan or PET-CT scan of the para–aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection)
Patients must be clinically staged according to the 7th edition (2010) of the American Joint Committee on Cancer (AJCC) staging system and must have either clinical T3-4a, or >= N1 disease; staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred)
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, magnetic resonance (MR) spectroscopy, or surgical/pathological documentation of disease
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). For subjects with treated central nervous system (CNS) disease, a head CT and/or brain/spinal magnetic resonance imaging (MRI) as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria.
Subjects may have completed concurrent chemoradiation with a standard chemotherapy regimen (cisplatin/etoposide, carboplatin/paclitaxel or cisplatin/pemetrexed [non-squamous only]) and a dose of radiation ranging from 59.4-66.6 Gy; subjects must have stable disease or disease response as evidenced on computed tomography (CT) or positron emission tomography (PET) scan evaluation; for those eligible, protocol therapy should begin a minimum of 28 days and a maximum 56 days following the completion of chemoradiation\r\nOR\r\nSubjects may have completed up to 2 cycles of consolidation therapy started within 4 weeks of completion of radiation; after completion of consolidation chemotherapy, subjects must have stable disease or disease response as evidenced by CT or PET scan evaluation; for those eligible, protocol therapy should begin 3-4 weeks after the last cycle of chemotherapy
Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to treatment; at a minimum, chest x-ray is required; computed tomography (CT) imaging of the chest or positron emission tomography (PET/CT) is acceptable
Achieved at least stable disease to salvage treatment determined by positron emission tomography (PET)/computed tomography (CT) using 2014 Lugano Classification prior to ASCT
Metastasis that is > 10 mm in longest dimension or exhibits radiotracer uptake consistent with metastasis on positron emission tomography/computed tomography (PET/CT)
fluorodeoxyglucose (FDG)-avid lymphoma (i.e., positron emission tomography (PET)-positive lymphoma)
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scans are required for full staging of metastatic disease prior to enrollment; if subject has had an FDG-PET/computed tomography (CT) scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: biopsy does not have to be performed at the time of enrollment for patients with recurrent disease as long as biopsy was performed at time of initial diagnosis
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy within 8 weeks of registration\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scans are required for full staging of metastatic disease; if subject has had an FDG-PET/CT scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: the primary site does not have to be the site of pathological confirmation; for example, in a patient with a radiographic lung lesion with mediastinal lymphadenopathy and a liver lesion, a liver biopsy which is constant with lung primary would preclude the necessity for further pathologic diagnosis
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration including resting heart rate;\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration; \r\n* Forced expiratory volume in one second (FEV1) >= 0.8 liter or >= 35% predicted with or without bronchodilator within 90 days prior to registration;\r\n** Patients who meet the criterion above without oxygen (O2), but who need acute (started within 10 days prior to registration) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable
Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan
Absence of distant metastases on standard diagnostic work-up =< 16 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], or positron emission tomography [PET]/CT)
Detectable disease by at least one of the following modalities: computed tomography (CT), positron emission tomography (PET), bone scan, or magnetic resonance imaging (MRI)
Non-secretors must have measurable disease such as plasmacytomas, or positron emission tomography (PET) avid lytic lesions or bone marrow plasmacytosis >= 30% at the time of relapse to be eligible
Positron emission tomography (PET) scan is suggested for a PSA >= 0.2 ngs/ml
No clinical evidence of metastatic spread; staging should include endoscopic ultrasound and positron emission tomography (PET)/computed tomography (CT) as recommended by National Comprehensive Cancer Network (NCCN) guidelines; PET/CT should be performed within 3 weeks of signing informed consent
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography (CT) or staging laparoscopy
Staged by positron emission tomography (PET)/computed tomography (CT) and esophagogastroduodenoscopy (EGD) OR CT without (w/) contrast and EGD to have stage II or III disease; endoscopic ultrasound (EUS) is encouraged but not required
Measurable disease, meaning at least 1 lymph node or other lymphomatous lesion with a long axis of ? 1.5 cm by computed tomography (CT) imaging, and at least one fluorodeoxyglucose (FDG)-avid lesion by FDG-positron emission tomography (PET) scan
If solitary lesion, metastasis confirmed with either biopsy or two independent imaging modalities (i.e. CT and PET [positron emission tomography], bone scan and MRI, modality at the discretion of the treating physician)
Metastatic prostate cancer (M1) as documented by appropriate medical imaging (i.e. computed tomography [CT]-scan, positron emission tomography [PET] scan or bone scan)
Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
Staging positron emission tomography (PET)/computed tomography (CT) (invasive mediastinal staging strongly encouraged but not required)
Patients must have a tissue diagnosis of diffuse large B cell lymphoma, with a negative positron emission tomography (PET)/computed tomography (CT) scan performed within 28 days of study enrollment, with one of the following clinical features: \r\n* High risk international prognostic index (IPI)\r\n* Activated B-cell–like (ABC)-subtype DLBCL\r\n* Double hit/ triple hit DLBCL
For Arm G, patients with disease beyond the pelvis, including but not limited to the para-aortic nodes as determined by positron emission tomography (PET)/CT will be excluded.
Positron emission tomography (PET)-computed tomography (CT) within the last 45 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Surgically resectable (T1-3 Nx by endoscopic ultrasound); excluded are:\r\n* Very early stage tumors (T1N0)\r\n* Cervical esophageal tumors\r\n* Tumors invading the tracheobronchial tree or associated with tracheoesophageal fistula\r\n* Any evidence of distant metastases (as determined by endoscopic ultrasound [EUS] or computed tomography/positron emission tomography [CT/PET])\r\n* Cervical, supraclavicular, or other nodal disease that is either not included in the radiation field or is not able to be resected at the time of esophagectomy
The patient is staged with endoscopic ultrasound (EUS)/esophago-gastro-duodenoscopy (EGD) and positron emission tomography (PET)/computed tomography (CT) scan
Clinically stage I disease by American Joint Committee on Cancer (AJCC) 7th edition (N0, M0, T stages T1-T2a) or patients with stage T2bN0M0 disease (clinical stage IIA), as determined by a computed tomography (CT) chest, abdomen, pelvis or a positron emission tomography (PET) CT =< 60 days of treatment start, who are medically unfit for standard of care chemotherapy as documented by a medical oncologist or radiation oncologist, or who refuse standard of care chemotherapy as documented by a medical oncologist or radiation oncologist
Staging by positron emission tomography (PET)-computed tomography (CT) scan (required) and magnetic resonance imaging (MRI) brain (if clinically indicated) showing no evidence of metastatic disease (mediastinoscopy is not required unless imaging is indeterminate and is then considered standard of care)
Positive 68Ga-PSMA-11 PET/CT (positron emission computed tomography ) or diagnostic 177Lu-PSMA-617 scintigraphy
Patients with Stage IV breast cancer are not eligible; baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms); if performed, reports of these examinations must be available; examination type for staging, i.e. X-ray, sonography, bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)-CT, is at the discretion of the investigator
Pathologically confirmed diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma with measurable bone marrow lymphoblasts or biopsy-proven extramedullary site measurable by computed tomography (CT) or positron emission tomography (PET)/CT imaging; Philadelphia chromosome-positive (Ph+) B-ALL patients must have failed treatment with at least one second generation tyrosine kinase inhibitor; prior allo-HCT is allowed
MRI of the pelvis or positron emission tomography (PET)-CT within 4 months before registration
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Patients must not have evidence of metastatic disease per positron emission tomography (PET)/ computed tomography (CT) scan; mediastinal lymph node involvement is acceptable
Patients must have received prior radiation therapy and must have an interval of greater than or equal to 12 weeks (84 days) from the completion of radiation therapy to study entry except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission tomography [PET] scan) in which case the principal investigator’s discretion may determine appropriate timepoint at which study therapy may begin
Have undergone a second-look surgery by a MD Anderson Gynecologic Oncology faculty after having achieved a complete clinical response to frontline surgery and adjuvant chemotherapy as evidenced by\r\n* Normal physical exam,\r\n* Normal computed tomography (CT) or positron emission tomography (PET)-CT of abdomen and pelvis or other equivalent imaging, and\r\n* Normalization of CA125 (< 35 U/mL)
Low-volume lung metastases are defined as solid pulmonary nodules < 2 cm with non-spiculated contours, no benign-appearing calcifications, and =< 14 in number, diagnosed by computed tomography of the chest or positron emission tomography (PET)
Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes < 2 cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography
Baseline imaging with an fludeoxyglucose (FDG)-positron emission tomography (PET) scan negative for distant metastatic disease must be obtained =< 28 days prior to registration
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Detectable positron emission tomography (PET)-positive disease
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging MRI]) disease documented after completion of prior systemic therapy
Any MPM histology (epithelial, mixed, sarcomatoid)\r\n* N0 or N1 nodal disease as present on preoperative chest computed tomography (CT) and/or positron emission tomography (PET)-CT\r\n* N2 nodule disease if no progression after 2 cycles of standard chemotherapy; progression will be considered if additional N1 or N2 disease develop during chemotherapy
Patients must have at least one bi-dimensionally measurable lesion by palpation, clinical exam, or radiographic imaging within 6 weeks of the start of study intervention (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Pathologic confirmation of NSCLC diagnosis is recommended whenever possible; this will generally be accomplished using computed tomography (CT) guided or bronchoscopic biopsies; if pathologic confirmation is not possible, a target lesion must be a non calcified pulmonary nodule that is present on at least 2 imaging studies (can include simulation scan); the nodule must have increased in size or proportion of solid component on CT and/or show increased fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) over at least 2 imaging studies
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new central nervous system (CNS) lesions are present, patient must have definitive treatment (including surgery or radiation); principal investigator (PI) or his designee should make final determination regarding enrollment
Patients must have documentation of relapse that includes either doubling of CA125 serum levels confirmed by measurements greater than one week apart or identification of a new measurable lesion greater than 1 cm in the peritoneal cavity either by computed tomography/magnetic resonance imaging (CT/MRI), positron emission tomography (PET)/CT scan or physical exam (expanding pockets of ascites fluid that may serve as an alternative source of tumor cells) if the index lesion is not accessible for biopsy for vaccine formulation; recurrence outside the peritoneal cavity will be accessed using standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria
The subject has documented worsening of disease (progressive disease) at screening compared with a previous computed tomography (CT) scan or magnetic resonance imaging (MRI) image done within 14 months of screening documentation of progression may be made by radiological (CT, MRI, or positron emission tomography [PET]), clinical or serological  assessment; if documentation is radiological, screening scan be compared to any previous scan (CT, MRI or PET) within 14 months of cycle 1 day 1 (C1D1)
Patients must have a positron emission tomography (PET) scan within 56 days of enrollment
Patients with prior therapy that included interstitial brachytherapy, or Gliadel wafers must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical documentation of disease
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Clinical T-stage (prior to systemic therapy, if applicable) >= T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or
Subjects must be diagnosed with either oropharyngeal or supraglottic squamous cell carcinoma\r\n* Primary tumor staging at T1, T2, or T3 based on contrasted neck computed tomography (CT), complete physical exam, and direct laryngoscopy; if possible, a positron emission tomography (PET) CT should also be collected; regardless of size, primary tumors must be mobile on physical exam and must not exhibit invasion of parapharyngeal fat on CT\r\n* Regional nodal metastases stages as N0, N1, or N2 without extracapsular spread (ECS)\r\n** N2a immediately eligible\r\n** N2b and N2c eligible when nodes are isolated (i.e., no conglomerate nodal masses)\r\n* No evidence of distant metastatic disease
Histologically confirmed adenocarcinoma of the pancreas or ampulla of Vater; at least the majority of the histopathologic specimen must be identified as adenocarcinoma as opposed to another histologic subtype\r\n* If histological confirmation of adenocarcinoma cannot be obtained by biopsy, the following procedures may be employed:\r\n** Attempt a repeat biopsy to obtain a diagnosis\r\n** Present the case at John Hopkins University (JHU) tumor board and if the candidate has one of the following: a rising cancer antigen (CA) 19-9 or radiographic evidence of recurrence on magnetic resonance imaging (MRI), computed tomography (CT), and/or positron emission tomography (PET) scan then the patient can be considered for treatment on protocol\r\n* However, if these objectives cannot be met, the patient will not be a candidate
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Locally advanced high-risk carcinoma of the uterine cervix, i.e.: intact cervix (i.e. non-operative) with International Federation of Gynecology and Obstetrics (FIGO) stage at least IB2 OR post-hysterectomy with either: residual gross disease or para-aortic nodal involvement (either resected or unresected) based upon standard diagnostic workup, including:\r\n* History/physical examination \r\n* Examination under anesthesia (if indicated)\r\n* Biopsy \r\n* Intravenous pyelogram and/or cystoscopy (if indicated)\r\n* Colonoscopy, sigmoidoscopy, or rigid proctoscopy (if indicated)\r\n* Posteroanterior (PA) and lateral chest x-ray or chest computed tomography (CT)\r\n* CT or magnetic resonance imaging (MRI) of the pelvis\r\n* Positron emission tomography (PET), PET/CT, or PET/CT simulation (encouraged)
Relapse/persistent disease evidenced by a computed tomography and fluorodeoxyglucose (FDG)-positron emission tomography (PET), or bone marrow biopsy
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical/pathological documentation of disease
Clinical stage II and III NSCLC based on American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to document nodal positivity include computed tomography (CT) chest, positron emission tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI)
No evidence of distant metastatic disease as documented by magnetic resonance imaging (MRI) of the brain and positron emission tomography (PET)/computed tomography (CT)
Patients must receive an magnetic resonance imaging (MRI)/computed tomography (CT) of the brain or positron emission tomography (PET)/CT within 6 months of consenting; if new lesions are present, principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Patients are eligible for transplantation if there is no evidence of progressive disease by imaging modalities or biopsy; persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Evidence of progressive disease by imaging modalities or biopsy-persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Staging evaluation within 42 days of enrollment consisting of staging laparoscopy, computed tomography (CT) scan of the abdomen and pelvis, and positron emission tomography (PET) scan will be acquired; also endoscopic ultrasound (EUS) tumor and nodal staging will be required
Positron emission tomography (PET)-positive disease
Bone scan within 120 days prior to enrollment; if the bone scan is suspicious, a plain x?ray and/or MRI must\r\nbe obtained to rule out metastasis, and advanced imaging (e.g., 18NaF positron emission tomography [PET]/CT) is strongly recommended
Must have pathologically-proven adenocarcinoma of the stomach or gastroesophageal (GE)-junction, stage M0, as established by both imaging and surgical pathologic staging.\r\n* Imaging: Clinical stage of M0 will be established by either computed tomography (CT) (chest with contrast and abdomen/pelvis with and without contrast), or CT/positron emission tomography (PET) (skull base to mid-thigh). This is standard post-surgery imaging.\r\n*Surgery: Surgical pathologic staging must be M0.
Must have American Joint Committee on Cancer (AJCC) 7th edition (ed) inoperable stage II disease requiring chemoradiation therapy or stage IIIA or IIIB NSCLC based on appropriate staging studies including brain magnetic resonance imaging (MRI) or head computed tomography (CT), CT chest, and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan
Patients must demonstrate >= 75% disease reduction on computed tomography (CT) scan (confirmed by positron emission tomography [PET] scan) after the third cycle of R-EPOCH relative to baseline, with no evidence of disease progression after the fifth cycle
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, positron emission tomography [PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not demonstrate metastatic disease and the requirements are met
Patients must undergo pre-treatment endoscopic tumor staging and positron emission tomography (PET)-computed tomography (CT) scanning
All responses are to be determined using the response criteria for non-hodgkin’s lymphoma and will include PET/computed tomography (CT) prior to hematopoietic cell transplantation (HCT)
Fluorodeoxyglucose (FDG)-avid disease by positive emission tomography (PET), and measurable disease greater than 1.5 cm in diameter
A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease greater than 1.5cm diameter
pathologically confirmed mantle cell lymphoma (MCL), with (a) measurable nodal disease on positron emission tomography computed tomography (PET-CT) per Lugano classification. Prior to enrollment, pathology must be reviewed and confirmed at the investigational site where the participant is entered
Subjects with HL with no available curative treatment options (such as autologous stem cell transplant [SCT]) who have a limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled\r\n* HL with biopsy-proven relapse or refractory disease who are unresponsive to or intolerant of at least one line of standard salvage therapy\r\n* Patients must have evaluable disease by radiologic imaging (fluorodeoxyglucose [FDG] positron emission tomography [PET]/computed tomography [CT] or PET/magnetic resonance imaging [MRI]) within 42 days of enrollment; evaluable includes both assessable and/or measurable disease as defined by Cheson et al., 2007
Metastatic lesions identifiable only by positron emission tomography (PET)
Patients must have a magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) of the brain within 2 months before consenting if known history of brain metastasis or if clinically indicated; if new lesions are present, principal investigator (PI) or designee should make final determination regarding enrollment
Subjects must have measurable or evaluable disease based on physical exam and/or radiographs (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]) or bone marrow involvement
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon positron emission tomography (PET), Thallium scanning, MR spectroscopy/perfusion, progression outside of radiation field, or surgical documentation of disease; if the additional imaging is unable to be performed for insurance or other reasons, the principal investigator (PI) will review the available imaging to determine if patients is eligible
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Presence of evaluable disease by positron emission tomography (PET) imaging per the Lugano classification
Histologically confirmed adenocarcinoma of the prostate with progressive metastatic disease which, in the opinion of the investigator, requires initiation of new treatment. The assessment of disease progression can be based on either PSA rise, new or progressive soft tissue disease (based on computed tomography [CT] or magnetic resonance imaging [MRI] scans), or new or progressive bony disease based on radionuclide bone scan or 18F-sodium fluoride positron emission tomography/computed tomography [NaF PET/CT] scans). Participants being considered for Cohort 2B must, in addition, have primary or metastatic lesions amenable to tumor biopsies
Standard staging exams for patients with high-risk prostate cancer including bone scan or sodium fluoride (NaF) positron emission tomography (PET)/CT scan, and pelvic and prostate MRI
Evidence of metastatic disease\r\n* NOTE: patients will not require baseline staging positron emission tomography (PET) or computed tomography (CT) chest, abdomen, pelvis or bone scan to rule out metastatic disease prior to enrollment; any staging scans will be ordered at the treating provider’s discretion; if metastatic disease is found on any staging studies done, patients will not be eligible for enrollment
ELIGIBILITY FOR TREATMENT ON ARM 1: Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
clinical and laboratory signs: rapid disease progression, high standardized uptake value (SUV) (> 12) by positron emission tomography (PET) at baseline if PET scans are performed (optional).
Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within 2 months (61 days: stage IIIB, IIIC or stage IV; must be computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]/CT) or 6 months (183 days: stage II or IIIA; may be chest x-ray, CT, MRI, or PET/CT)
Staging studies with a computed tomography (CT) scan of the chest and abdomen and bone scan, or a positron emission tomography (PET)/CT is required for clinical stage III, and are considered optional for stage II breast cancers
Appropriate stage for protocol entry based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration
Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging (MRI) of brain and orbits with and without gadolinium; MRI may be done within 21 days prior to study entry\r\n* Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone scan (or fludeoxyglucose F-18 [FDG] positron emission tomography [PET] scan), and/or any other additional tests done at study entry; (Note: these tests are required only with specific indications for required observations)
Distant metastatic disease limited to peritoneum and radiologically occult (not visualized on preoperative imaging to include [computerized tomography] CT scan, ultrasound, [magnetic resonance imaging] MRI, positron emission tomography [PET]/CT): \r\n* Positive peritoneal cytology\r\n* Carcinomatosis on diagnostic laparoscopy or laparotomy
Patients can have up to only 6 discrete active extracranial lesions (=< 3 in the liver and =< 3 in the lung) identified by diagnostic computed tomography (CT) or positron emission tomography (PET)/CT scan or magnetic resonance imaging (MRI) within 8 weeks prior to the initiation of SBRT\r\n* For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months\r\n* Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months\r\n* Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply\r\n* Up to 2 contiguous vertebral metastases will be considered a single site of disease
Positron emission tomography (PET)/CT, x-ray or CT-scan of chest showing no evidence of metastatic disease
Absence of distant metastases on standard diagnostic work-up =< 10 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], positron emission tomography [PET]/CT, etc.)
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical/pathological documentation of disease
Complete radiology or tumor assessment within 28 days of randomization\r\n* Breast magnetic resonance imaging (MRI)\r\n* Unilateral breast ultrasound\r\n* Distant metastatic work-up completed with positron emission tomography (PET)/computed tomography (CT) or CT chest, abdomen, pelvis and bone scan\r\n* If enlarged axillary lymph nodes are found during staging scans, fine needle aspiration (FNA) must be performed to determine whether the node is involved with cancer\r\n* If axillary lymph nodes are clinically negative during initial work-up, sentinel node biopsy may be performed prior to initiation of chemotherapy
Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria)
Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine which may include computer assisted tomography (CAT scan), positron emitted tomography (PET) or nuclear medicine bone scan (NMBS); magnetic resonance imaging (MRI) is required prior to treatment planning to confirm the extent of the disease and is used for defining the target for the radiation
Metastatic disease on bone scan and/or involvement of soft tissues (lymph nodes and/or viscera) by computed tomography (CT) scan, positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)
Patients must have been evaluated by standard-of-care full body imaging studies (computed tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction HDI-ipilimumab (at 6-8 weeks after the first dose of ipilimumab/HDI and prior to the definitive lymphadenectomy procedure)
Systemic involvement (i.e., nodal, bone marrow or visceral organ involvement) will be evaluated by computed tomography (CT) and/or positron emission tomography (PET) and bone marrow biopsy (if indicated on patients with blood involvement) in patients with pc-ALCL or MF at baseline
Deauville score of 1-3 on post-chemotherapy (or interim) positron emission tomography (PET) scan
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 30 days prior to registration;\r\n* Imaging of the primary tumor by MRI and/or computed tomography (CT) with and without contrast and/or positron emission tomography (PET)/CT within 60 days prior to registration;\r\n* Staging workup evaluated by chest CT and/or PET/CT showing no distant metastasis within 60 days prior to registration
All oncologists and radiologists will review positron emission tomography (PET) scans prior to therapy as standard practice to confirm eligibility
Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by:\r\n* EITHER computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis, OR endorectal MRI of the pelvis that demonstrate no nodes > 1.5 cm\r\n* If one or more pelvic lymph node(s) measures > 1.5 cm, a negative biopsy is required; if more than one lymph node is > 1.5 cm, the largest or most accessible node should be biopsied; AND\r\n* Negative bone scan (with plain films and/or MRI and/or CT scan confirmation, if necessary)\r\nPositive positron emission tomography (PET) and ProstaScint scans are not considered proof of metastatic disease
Positron emission tomography (PET)/computed tomography (CT) is required for all patients, unless contraindicated; this may be acquired prior to study entry or after enrollment prior to SBRT planning
Metastatic disease beyond the neck or supraclavicular area as demonstrated by positron emission tomography (PET)/CT or biopsy
Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Patient must have histologically proven primary or recurrent extremity melanoma, stage IIIB, IIIC, or stage IV (American Joint Committee on Cancer [AJCC] staging must be documented in patient’s medical record, as determined by computed tomography [CT] of the chest, abdomen and pelvis, and/or whole body positron emission tomography [PET] scan, and magnetic resonance imaging [MRI] of the brain within 4 weeks prior to administration of study drug)
Patients must have been evaluated by standard-of-care full body imaging studies (computerized tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction nivolumab-ipilimumab or nivolumab alone (at 6-8 weeks after the first dose of induction and prior to the definitive surgery procedure)
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET).
Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan For enrollment in part 2, patients must meet all of the following:
Patients must have pathologic diagnosis of non-small cell lung carcinoma (NSCLC), by either histologic biopsy, or cytologic evidence; highly suspicious cytology (i.e. abnormal cells suspicious for malignancy) is acceptable, in the setting of a strongly positive computed tomography (CT)/positron emission tomography (PET) (standardized uptake value [SUV] > 5.0)
Systemic staging including computed tomography (CT) that covers the chest, liver and adrenal glands or a positron emission tomography (PET)/CT; magnetic resonance imaging (MRI) of the brain is required and must be negative for metastatic spread; if a patient is unable to tolerate MRI or has a contraindication to MRI, a head CT scan with and without contrast is acceptable
There must be an interval of at least 12 weeks from the completion of radiotherapy to start of device treatment; when the interval is less than 12 weeks from the completion of radiotherapy, the histological confirmation of progression must be unequivocal per Revised Assessment in Neuro-Oncology (RANO) criteria; the use of positron emission tomography (PET) scan, perfusion imaging, and magnetic resonance (MR) spectroscopy to differentiate between true early progression and pseudoprogression prior to biopsy or resection of probable recurrent tumor is per standard of care
No evidence of metastatic disease on imaging by whole body bone scan (technetium-99 or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within 6 weeks of day 1 of protocol therapy
N2-3 lymph node involvement based on positron emission tomography (PET)/endobronchial ultrasound-fine needle aspiration (EBUS-FNA)/mediastinoscopy (any N2 disease that is more than just minimal single station involvement is excluded)
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable quality to the central radiology laboratory prior to Cycle 1 Day 1.
Patients must have failed prior external beam radiation therapy; a positron emission tomography (PET) or thallium single photon emission computed tomography (SPECT), MR spectroscopy and MR perfusion, or surgical documentation may be done at the discretion of the treating physician if there is a question of radiation changes/necrosis versus progressive disease
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography [CT] or staging laparoscopy)
Positron emission tomography (PET) avid disease with standard uptake value (SUV) > 5
Centers that standardly use positron emission tomography (PET) or magnetic resonance spectroscopy (MRS) to determine a diagnosis of radionecrosis are permitted to use these modalities to assist in their patient selection; however the criteria described for conventional MR and/or DSC should also be met for study eligibility; both PET and MRS are not mandatory for study eligibility
Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
Patients with any radiographic evidence of metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or positron emission tomography (PET) scan
Patients must have cross-sectional body imaging (positron emission tomography [PET]-computed tomography [CT] or equivalent) performed within 4 weeks of study enrollment and available for review
Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid tumors
The patient has received a clinical classification of stage I or II disease; \clinically classified\ means using all studies including computed tomography (CT) scans, positron emission tomography (PET) scans, bone scans, mediastinoscopy, and/or any study or procedure performed short of thoracotomy
Subjects must have had a baseline scan (computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography-computer tomography [PET/CT]) of the chest to assess disease burden before starting on first line chemotherapy for NSCLC and those images must have been reviewed by the investigator prior to randomization. If the scan was performed more than 28 days prior to randomization, an additional scan must be performed and reviewed by the investigator to confirm that the patient has not progressed before randomization.
No evidence of relapsed or residual malignancy within 30 days of trial entry; all patients must undergo appropriate staging for their malignancy (i.e. bone marrow aspiration for the leukemias and positron emission tomography [PET]-computed tomography [CT] scanning for the lymphomas); evidence of a persistent cytogenetic abnormality will constitute evidence of residual or relapsed disease in the leukemias, where present; individuals with chronic lymphocytic leukemia (CLL) are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry
NHL\r\n* No clinical evidence of disease or disease-related symptoms\r\n* Typically fludeoxyglucose (FDG)-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is positron emission tomography (PET) negative\r\n* Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by computed tomography (CT)\r\n* Spleen and liver non-palpable and without nodules\r\n* If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Subject must have positron emission tomography (PET)-positive disease as per Lugano Classification
N2 lymph nodes negative on positron emission tomography (PET) scan or mediastinoscopy
Participants must have no evidence of nodal involvement (N0) or distant metastases (M0) on staging studies, which may include positron emission tomography (PET), computed tomography (CT), and/or mediastinoscopy
Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. 18F-DA PET/computed tomography (CT) scanning will not be the initial imaging study in a newly diagnosed patient
Stage T1-4aN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* Computed tomography (CT) chest/abdomen with contrast \r\n* Positron emission tomography (PET)/CT of the whole-body or skull base to mid-thigh\r\n* Patients must have regional adenopathy and have undergone endoscopic biopsy with endoscopic ultrasound (EUS)-proven peri-esophageal nodal involvement
Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan
Patients that have early stage non-small cell lung cancer or clinical suspicion of the same in cases where the lesion is not amenable to biopsy but is enlarging and positron emission tomography (PET)-positive; all patients are to be treated with stereotactic body radiation therapy as a monotherapy
Negative pregnancy test within 7 days of baseline positron emission tomography (PET) scan for pre-menopausal patients
Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm in diameter on axial imaging (CT or MRI or positron emission tomography [PET]/CT)